PERK
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A5A3E0 | S1065 | Sugiyama | POTEF A26C1B | ILASLSTFQQMWISKQEyDEsGPsIVHRKCL__________ |
| A5A3E0 | S1068 | Sugiyama | POTEF A26C1B | SLSTFQQMWISKQEyDEsGPsIVHRKCL_____________ |
| A6NMY6 | S164 | Sugiyama | ANXA2P2 ANX2L2 ANX2P2 LPC2B | NRVyKEMYKtDLEKDIIsDtsGDFRKLMVALAKGRRAEDGS |
| O14950 | T129 | Sugiyama | MYL12B MRLC2 MYLC2B | CFDEEATGTIQEDYLRELLttMGDRFtDEEVDELyREAPID |
| O14950 | T160 | Sugiyama | MYL12B MRLC2 MYLC2B | DELyREAPIDKKGNFNyIEFtRILKHGAKDKDD________ |
| O43852 | S69 | Sugiyama | CALU | HDAFLGAEEAKtFDQLtPEEsKERLGKIVSKIDGDKDGFVt |
| O60841 | S196 | Sugiyama | EIF5B IF2 KIAA0741 | ERsRINssGEsGDEsDEFLQsRKGQKKNQKNKPGPNIEsGN |
| O60841 | S222 | Sugiyama | EIF5B IF2 KIAA0741 | KNQKNKPGPNIEsGNEDDDAsFKIKTVAQKKAEKKERERKK |
| O60841 | S66 | Sugiyama | EIF5B IF2 KIAA0741 | KEKKKQDFDEDDILKELEELsLEAQGIKADREtVAVKPTEN |
| O60841 | T92 | Sugiyama | EIF5B IF2 KIAA0741 | IKADREtVAVKPTENNEEEFtsKDKKKKGQKGKKQsFDDND |
| O60927 | T75 | Sugiyama | PPP1R11 HCGV TCTE5 | RRssKCCCIyEKPRAFGEsstEsDEEEEEGCGHtHCVRGHR |
| O75821 | S189 | Sugiyama | EIF3G EIF3S4 | CPYKDtLGPMQKELAEQLGLstGEKEKLPGELEPVQAtQNK |
| O95218 | S153 | Sugiyama | ZRANB2 ZIS ZNF265 | KYRGKAVGPAsILKEVEDKEsEGEEEDEDEDLsKyKLDEDE |
| O95218 | S165 | Sugiyama | ZRANB2 ZIS ZNF265 | LKEVEDKEsEGEEEDEDEDLsKyKLDEDEDEDDADLsKyNL |
| O95218 | S181 | Sugiyama | ZRANB2 ZIS ZNF265 | DEDLsKyKLDEDEDEDDADLsKyNLDAsEEEDsNKKKSNRR |
| P04075 | S36 | Sugiyama | ALDOA ALDA | LsDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENR |
| P04075 | S360 | Sugiyama | ALDOA ALDA | QGKytPsGQAGAAAsEsLFVsNHAy________________ |
| P04075 | T37 | Sugiyama | ALDOA ALDA | sDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRR |
| P04083 | S189 | Sugiyama | ANXA1 ANX1 LPC1 | tsDtsGDFRNALLsLAKGDRsEDFGVNEDLADsDARALyEA |
| P05198 | S49 | EPSD|PSP | EIF2S1 EIF2A | EMGAYVSLLEYNNIEGMILLsELsRRRIRSINKLIRIGRNE |
| P05198 | S52 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | EIF2S1 EIF2A | AYVSLLEYNNIEGMILLsELsRRRIRSINKLIRIGRNECVV |
| P05198 | T284 | Sugiyama | EIF2S1 EIF2A | EKRGVFNVQMEPKVVtDtDEtELARQMERLERENAEVDGDD |
| P05455 | S325 | Sugiyama | SSB | VLEGEVEKEALKKIIEDQQEsLNKWKSKGRRFKGKGKGNKA |
| P06733 | T205 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | GAEVyHNLKNVIKEKyGKDAtNVGDEGGFAPNILENKEGLE |
| P07195 | T323 | Sugiyama | LDHB | sVINQKLKDDEVAQLKKsADtLWDIQKDLKDL_________ |
| P07355 | S164 | Sugiyama | ANXA2 ANX2 ANX2L4 CAL1H LPC2D | NRVyKEMYKtDLEKDIIsDtsGDFRKLMVALAKGRRAEDGs |
| P07437 | T55 | Sugiyama | TUBB TUBB5 OK/SW-cl.56 | tyHGDsDLQLDRIsVyyNEAtGGKyVPRAILVDLEPGtMDs |
| P07900 | T305 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | IDQEELNKtKPIWtRNPDDItNEEyGEFyKsLtNDWEDHLA |
| P08670 | S299 | Sugiyama | VIM | VAAKNLQEAEEWyKSKFADLsEAANRNNDALRQAKQESTEY |
| P08708 | S89 | Sugiyama | RPS17 RPS17L | ISIKLQEEERERRDNyVPEVsALDQEIIEVDPDtKEMLKLL |
| P09382 | T58 | Sugiyama | LGALS1 | DsNNLCLHFNPRFNAHGDANtIVCNsKDGGAWGTEQREAVF |
| P09467 | S170 | PSP | FBP1 FBP | EKDALQPGRNLVAAGYALYGsATMLVLAMDCGVNCFMLDPA |
| P0CG38 | S1065 | Sugiyama | POTEI | ILASLSTFQQMWISKQEyDEsGPsIVHRKCF__________ |
| P0CG38 | S1068 | Sugiyama | POTEI | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P0CG39 | S1028 | Sugiyama | POTEJ | ILASLSTFQQMWISKQEyDEsGPsIVHRKCF__________ |
| P0CG39 | S1031 | Sugiyama | POTEJ | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P10412 | T45 | Sugiyama | H1-4 H1F4 HIST1H1E | RKsAGAAKRKAsGPPVsELItKAVAASKERsGVsLAALKKA |
| P11940 | T191 | Sugiyama | PABPC1 PAB1 PABP PABP1 PABPC2 | GRFKSRKEREAELGARAKEFtNVyIKNFGEDMDDERLKDLF |
| P13639 | S593 | Sugiyama | EEF2 EF2 | SDPVVsyREtVsEEsNVLCLsKsPNKHNRLyMKARPFPDGL |
| P14314 | T115 | Sugiyama | PRKCSH G19P1 | GVCDCCDGtDEyNsGVICENtCKEKGRKEREsLQQMAEVtR |
| P14854 | S52 | Sugiyama | COX6B1 COX6B | QNyLDFHRCQKAMTAKGGDIsVCEWyQRVYQsLCPtsWVTD |
| P15311 | S535 | Sugiyama | EZR VIL2 | EKRITEAEKNERVQRQLLtLssELsQARDENKRTHNDIIHN |
| P15311 | S539 | Sugiyama | EZR VIL2 | TEAEKNERVQRQLLtLssELsQARDENKRTHNDIIHNENMR |
| P15311 | T425 | Sugiyama | EZR VIL2 | RQAVDQIKsQEQLAAELAEytAKIALLEEARRRKEDEVEEW |
| P15311 | T533 | Sugiyama | EZR VIL2 | NEEKRITEAEKNERVQRQLLtLssELsQARDENKRTHNDII |
| P16402 | T46 | Sugiyama | H1-3 H1F3 HIST1H1D | KAGATAGKRKAsGPPVsELItKAVAASKERsGVsLAALKKA |
| P16403 | T45 | Sugiyama | H1-2 H1F2 HIST1H1C | AKKAGGtPRKAsGPPVsELItKAVAASKERsGVsLAALKKA |
| P19105 | T128 | Sugiyama | MYL12A MLCB MRLC3 RLC | CFDEEATGTIQEDYLRELLttMGDRFtDEEVDELyREAPID |
| P19105 | T159 | Sugiyama | MYL12A MLCB MRLC3 RLC | DELyREAPIDKKGNFNyIEFtRILKHGAKDKDD________ |
| P19338 | S619 | Sugiyama | NCL | RIVTDRETGssKGFGFVDFNsEEDAKAAKEAMEDGEIDGNK |
| P20290 | S201 | Sugiyama | BTF3 NACB OK/SW-cl.8 | AtGEDDDDEVPDLVENFDEAsKNEAN_______________ |
| P23528 | T63 | Sugiyama | CFL1 CFL | DKKNIILEEGKEILVGDVGQtVDDPyAtFVKMLPDKDCRyA |
| P23528 | Y68 | Sugiyama | CFL1 CFL | ILEEGKEILVGDVGQtVDDPyAtFVKMLPDKDCRyALyDAt |
| P23588 | S122 | Sugiyama | EIF4B | NLPyDVTEESIKEFFRGLNIsAVRLPREPsNPERLKGFGyA |
| P24844 | T129 | Sugiyama | MYL9 MLC2 MRLC1 MYRL2 | CFDEEASGFIHEDHLRELLttMGDRFtDEEVDEMyREAPID |
| P26038 | S576 | Sugiyama | MSN | YKtLRQIRQGNTKQRIDEFEsM___________________ |
| P27797 | S53 | Sugiyama | CALR CRTC | WtsRWIEsKHKSDFGKFVLssGKFyGDEEKDKGLQTSQDAR |
| P27797 | T34 | Sugiyama | CALR CRTC | LAVAEPAVYFKEQFLDGDGWtsRWIEsKHKSDFGKFVLssG |
| P29401 | T342 | Sugiyama | TKT | GQALAKLGHAsDRIIALDGDtKNstFsEIFKKEHPDRFIEC |
| P30050 | S157 | Sugiyama | RPL12 | QsVGCNVDGRHPHDIIDDINsGAVECPAs____________ |
| P30101 | T485 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | KKyEGGRELsDFIsyLQREAtNPPVIQEEKPKKKKKAQEDL |
| P35579 | S1154 | Sugiyama | MYH9 | KRDLGEELEALKtELEDtLDstAAQQELRSKREQEVNILKK |
| P35579 | S1713 | Sugiyama | MYH9 | ERAKRQAQQERDELADEIANssGKGALALEEKRRLEARIAQ |
| P35579 | S1714 | Sugiyama | MYH9 | RAKRQAQQERDELADEIANssGKGALALEEKRRLEARIAQL |
| P35579 | S1892 | Sugiyama | MYH9 | LKQLKRQLEEAEEEAQRANAsRRKLQRELEDAtEtADAMNR |
| P35579 | S1915 | Sugiyama | MYH9 | KLQRELEDAtEtADAMNREVssLKNKLRRGDLPFVVPRRMA |
| P35579 | T1146 | Sugiyama | MYH9 | sRNKAEKQKRDLGEELEALKtELEDtLDstAAQQELRSKRE |
| P35579 | T1155 | Sugiyama | MYH9 | RDLGEELEALKtELEDtLDstAAQQELRSKREQEVNILKKT |
| P35579 | T1208 | Sugiyama | MYH9 | QEMRQKHsQAVEELAEQLEQtKRVKANLEKAKQtLENERGE |
| P35579 | T1904 | Sugiyama | MYH9 | EEAQRANAsRRKLQRELEDAtEtADAMNREVssLKNKLRRG |
| P35580 | T1911 | Sugiyama | MYH10 | EEATRANASRRKLQRELDDAtEANEGLSREVSTLKNRLRRG |
| P37802 | T180 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | RNFsDNQLQEGKNVIGLQMGtNRGAsQAGMtGyGMPRQIL_ |
| P39019 | T55 | Sugiyama | RPS19 | DtVKLAKHKELAPyDENWFytRAAstARHLYLRGGAGVGsM |
| P39019 | Y54 | Sugiyama | RPS19 | VDtVKLAKHKELAPyDENWFytRAAstARHLYLRGGAGVGs |
| P46777 | S224 | Sugiyama | RPL5 MSTP030 | VADyMRyLMEEDEDAyKKQFsQyIKNsVtPDMMEEMyKKAH |
| P46783 | T148 | Sugiyama | RPS10 | RRSAVPPGADKKAEAGAGsAtEFQFRGGFGRGRGQPPQ___ |
| P53999 | S118 | Sugiyama | SUB1 PC4 RPO2TC1 | PGRKGIsLNPEQWsQLKEQIsDIDDAVRKL___________ |
| P53999 | S9 | Sugiyama | SUB1 PC4 RPO2TC1 | ____________MPKSKELVsssssGsDsDsEVDKKLKRKK |
| P58546 | T108 | Sugiyama | MTPN | LSKGADKTVKGPDGLTAFEAtDNQAIKALLQ__________ |
| P60660 | T22 | Sugiyama | MYL6 | CDFTEDQTAEFKEAFQLFDRtGDGKILysQCGDVMRALGQN |
| P60709 | S365 | Sugiyama | ACTB | ILAsLstFQQMWISKQEyDEsGPsIVHRKCF__________ |
| P60709 | S368 | Sugiyama | ACTB | sLstFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P61247 | S203 | Sugiyama | RPS3A FTE1 MFTL | EVVNKLIPDsIGKDIEKACQsIyPLHDVFVRKVKMLKKPKF |
| P61247 | S236 | Sugiyama | RPS3A FTE1 MFTL | KMLKKPKFELGKLMELHGEGsssGKAtGDEtGAKVERADGy |
| P61247 | Y205 | Sugiyama | RPS3A FTE1 MFTL | VNKLIPDsIGKDIEKACQsIyPLHDVFVRKVKMLKKPKFEL |
| P61254 | S12 | Sugiyama | RPL26 | _________MKFNPFVtsDRsKNRKRHFNAPsHIRRKIMss |
| P61254 | T8 | Sugiyama | RPL26 | _____________MKFNPFVtsDRsKNRKRHFNAPsHIRRK |
| P61313 | S100 | Sugiyama | RPL15 EC45 TCBAP0781 | tyGKPVHHGVNQLKFARsLQsVAEERAGRHCGALRVLNsyW |
| P61981 | T31 | Sugiyama | YWHAG | ARLAEQAERyDDMAAAMKNVtELNEPLsNEERNLLsVAyKN |
| P62249 | S9 | Sugiyama | RPS16 | ____________MPsKGPLQsVQVFGRKKTATAVAHCKRGN |
| P62258 | S148 | Sugiyama | YWHAE | YHRyLAEFAtGNDRKEAAENsLVAyKAAsDIAMtELPPTHP |
| P62269 | Y95 | Sugiyama | RPS18 D6S218E | RQYKIPDWFLNRQKDVKDGKysQVLANGLDNKLREDLERLK |
| P62277 | S12 | Sugiyama | RPS13 | _________MGRMHAPGKGLsQsALPyRRsVPtWLKLTsDD |
| P62280 | T54 | Sugiyama | RPS11 | PRYYKNIGLGFKtPKEAIEGtyIDKKCPFTGNVsIRGRILs |
| P62424 | T84 | Sugiyama | RPL7A SURF-3 SURF3 | QRQRAILyKRLKVPPAINQFtQALDRQTAtQLLKLAHKYRP |
| P62857 | T38 | Sugiyama | RPS28 | LGRtGsQGQCtQVRVEFMDDtsRsIIRNVKGPVREGDVLtL |
| P62899 | T119 | Sugiyama | RPL31 | PNKLytLVtyVPVttFKNLQtVNVDEN______________ |
| P62979 | T147 | Sugiyama | RPS27A UBA80 UBCEP1 | GAGVFMAsHFDRHyCGKCCLtyCFNKPEDK___________ |
| P63104 | T30 | Sugiyama | YWHAZ | AKLAEQAERyDDMAACMKsVtEQGAELsNEERNLLsVAyKN |
| P63173 | T14 | Sugiyama | RPL38 | _______MPRKIEEIKDFLLtARRKDAKSVKIKKNKDNVKF |
| P63261 | S365 | Sugiyama | ACTG1 ACTG | ILAsLstFQQMWISKQEyDEsGPsIVHRKCF__________ |
| P63261 | S368 | Sugiyama | ACTG1 ACTG | sLstFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| P67809 | S314 | Sugiyama | YBX1 NSEP1 YB1 | NPKPQDGKETKAADPPAENssAPEAEQGGAE__________ |
| P67809 | T108 | Sugiyama | YBX1 NSEP1 YB1 | QtAIKKNNPRKyLRsVGDGEtVEFDVVEGEKGAEAANVtGP |
| P67809 | Y99 | Sugiyama | YBX1 NSEP1 YB1 | DtKEDVFVHQtAIKKNNPRKyLRsVGDGEtVEFDVVEGEKG |
| P68363 | T73 | Sugiyama | TUBA1B | FsEtGAGKHVPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLI |
| P68363 | T82 | Sugiyama | TUBA1B | VPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANN |
| P68363 | Y83 | Sugiyama | TUBA1B | PRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANNy |
| P84098 | S37 | Sugiyama | RPL19 | CGKKKVWLDPNEtNEIANANsRQQIRKLIKDGLIIRKPVtV |
| P84098 | T29 | Sugiyama | RPL19 | RLAssVLRCGKKKVWLDPNEtNEIANANsRQQIRKLIKDGL |
| Q01105 | S165 | Sugiyama | SET | PyFENKVLSKEFHLNEsGDPssKstEIKWKSGKDLTKRssQ |
| Q08J23 | S593 | Sugiyama | NSUN2 SAKI TRM4 | NNSEKMKVINTGIKVWCRNNsGEEFDCAFRLAQEGIYTLYP |
| Q13310 | T191 | Sugiyama | PABPC4 APP1 PABP4 | GRFKSRKEREAELGAKAKEFtNVyIKNFGEEVDDEsLKELF |
| Q13428 | S1376 | Sugiyama | TCOF1 | ARtPRSKKKKKLGAGEGGEAsVsPEKtsttSKGKAKRDKAS |
| Q13765 | S132 | Sugiyama | NACA HSD48 | YKSPAsDtyIVFGEAKIEDLsQQAQLAAAEKFKVQGEAVsN |
| Q14247 | T328 | Sugiyama | CTTN EMS1 | GKyGVQKDRMDKNAstFEDVtQVssAyQKTVPVEAVtsKts |
| Q14444 | T103 | Sugiyama | CAPRIN1 GPIAP1 GPIP137 M11S1 RNG105 | NKGERLNQDQLDAVsKyQEVtNNLEFAKELQRsFMALsQDI |
| Q14684 | S392 | Sugiyama | RRP1B KIAA0179 | EKTNLEKEKGSRVFCVEEEDsEssLQKRRRKKKKKHHLQPE |
| Q15056 | S110 | Sugiyama | EIF4H KIAA0038 WBSCR1 WSCR1 | DEVDsLKEALtyDGALLGDRsLRVDIAEGRKQDKGGFGFRK |
| Q27J81 | S1202 | Sugiyama | INF2 C14orf151 C14orf173 | EsALDtsLDKsFsEDAVtDssGsGtLPRARGRASKGTGKRR |
| Q6S8J3 | S1065 | Sugiyama | POTEE A26C1A POTE2 | ILASLSTFQQMWISKQEyDEsGPsIVHRKCF__________ |
| Q6S8J3 | S1068 | Sugiyama | POTEE A26C1A POTE2 | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| Q71U36 | T73 | Sugiyama | TUBA1A TUBA3 | FsEtGAGKHVPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLI |
| Q71U36 | T82 | Sugiyama | TUBA1A TUBA3 | VPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANN |
| Q71U36 | Y83 | Sugiyama | TUBA1A TUBA3 | PRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANNy |
| Q8NFD5 | S1744 | Sugiyama | ARID1B BAF250B DAN15 KIAA1235 OSA2 | ALDTINILLYDDSTVATFNLsQLSGFLELLVEYFRKCLIDI |
| Q8TAM6 | S280 | Sugiyama | ERMN KIAA1189 | TISYRKIRKGNTKQRIDEFEsMMHL________________ |
| Q96SQ9 | T131 | Sugiyama | CYP2S1 UNQ891/PRO1906 | FDGHGVFFSNGERWRQLRKFtMLALRDLGMGKREGEELIQA |
| Q99848 | S270 | Sugiyama | EBNA1BP2 EBP2 | FGGKKKGSKWNtREsyDDVssFRAKTAHGRGLKRPGKKGSN |
| Q9BQ16 | T118 | Sugiyama | SPOCK3 TICN3 UNQ409/PRO771 | HKVCIAQDSQTAVCISHRRLtHRMKEAGVDHRQWRGPILST |
| Q9BQE3 | T73 | Sugiyama | TUBA1C TUBA6 | FsEtGAGKHVPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLI |
| Q9BQE3 | T82 | Sugiyama | TUBA1C TUBA6 | VPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANN |
| Q9BQE3 | Y83 | Sugiyama | TUBA1C TUBA6 | PRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANNy |
| Q9BYX7 | S365 | Sugiyama | POTEKP ACTBL3 FKSG30 | ILASLSTFQQMWISKQEyDEsGPsIVHRKCF__________ |
| Q9BYX7 | S368 | Sugiyama | POTEKP ACTBL3 FKSG30 | SLSTFQQMWISKQEyDEsGPsIVHRKCF_____________ |
| Q9H1E3 | Y146 | Sugiyama | NUCKS1 NUCKS JC7 | QEKDsGsDEDFLMEDDDDsDyGSsKKKNKKMVKKSKPERKE |
| Q9NQ39 | T159 | Sugiyama | RPS10P5 RPS10L | RRCSVPPGADKKAEAGAGsAtEFQFRGRCGRGRGQPPQ___ |
| Q9NZJ5 | S715 | Sugiyama | EIF2AK3 PEK PERK | VKIRRMDPFATKEHIEIIAPsPQRsRSFSVGISCDQTSSSE |
| Q9NZJ5 | T982 | PSP | EIF2AK3 PEK PERK | MDQDEEEQTVLTPMPAYARHtGQVGTKLYMSPEQIHGNSYS |
| Q9NZJ5 | Y619 | SIGNOR | EIF2AK3 PEK PERK | LGRGGFGVVFEAKNKVDDCNyAIKRIRLPNRELAREKVMRE |
| Q9UNX3 | S12 | Sugiyama | RPL26L1 RPL26P1 | _________MKFNPFVtsDRsKNRKRHFNAPSHVRRKIMss |
| Q9UNX3 | T8 | Sugiyama | RPL26L1 RPL26P1 | _____________MKFNPFVtsDRsKNRKRHFNAPSHVRRK |
| Q9Y3U8 | S91 | Sugiyama | RPL36 | KFIKKRVGTHIRAKRKREELsNVLAAMRKAAAKKD______ |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle | R-HSA-1640170 | 7.756795e-12 | 11.110 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 5.189422e-10 | 9.285 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 1.671072e-09 | 8.777 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 2.284455e-09 | 8.641 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 2.938838e-09 | 8.532 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 7.622142e-08 | 7.118 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 9.615088e-08 | 7.017 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 9.694096e-08 | 7.013 | 0 | 0 |
| M Phase | R-HSA-68886 | 2.417874e-07 | 6.617 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 3.512625e-07 | 6.454 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 4.257009e-07 | 6.371 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 5.580335e-07 | 6.253 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 8.626798e-07 | 6.064 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 1.278566e-06 | 5.893 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 1.947247e-06 | 5.711 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 2.657785e-06 | 5.575 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 2.981623e-06 | 5.526 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 4.544424e-06 | 5.343 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 4.390376e-06 | 5.357 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 4.784852e-06 | 5.320 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 6.283195e-06 | 5.202 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 6.813902e-06 | 5.167 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 7.254880e-06 | 5.139 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 7.254880e-06 | 5.139 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 9.312603e-06 | 5.031 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 9.888343e-06 | 5.005 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 1.365672e-05 | 4.865 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 1.739818e-05 | 4.759 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 1.754288e-05 | 4.756 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 1.876321e-05 | 4.727 | 1 | 0 |
| Nervous system development | R-HSA-9675108 | 2.044276e-05 | 4.689 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 2.278303e-05 | 4.642 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 2.278303e-05 | 4.642 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 2.289376e-05 | 4.640 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 2.480263e-05 | 4.606 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 2.549580e-05 | 4.594 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 3.101846e-05 | 4.508 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 3.657881e-05 | 4.437 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 4.795665e-05 | 4.319 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 5.032926e-05 | 4.298 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 5.135478e-05 | 4.289 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 5.507368e-05 | 4.259 | 0 | 0 |
| Kinesins | R-HSA-983189 | 5.536293e-05 | 4.257 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 5.899093e-05 | 4.229 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 6.719499e-05 | 4.173 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 1.149750e-04 | 3.939 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 1.113496e-04 | 3.953 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 1.221872e-04 | 3.913 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 1.184894e-04 | 3.926 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.277045e-04 | 3.894 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 1.334908e-04 | 3.875 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 1.659234e-04 | 3.780 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.047793e-04 | 3.689 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 2.219137e-04 | 3.654 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 2.669016e-04 | 3.574 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 2.660515e-04 | 3.575 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 2.376891e-04 | 3.624 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 2.704365e-04 | 3.568 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 2.611938e-04 | 3.583 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 2.682574e-04 | 3.571 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 2.508026e-04 | 3.601 | 1 | 1 |
| Signaling by ALK in cancer | R-HSA-9700206 | 2.508026e-04 | 3.601 | 1 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 3.672301e-04 | 3.435 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 4.692492e-04 | 3.329 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 5.538082e-04 | 3.257 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 5.787669e-04 | 3.237 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 6.325438e-04 | 3.199 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 6.087514e-04 | 3.216 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 6.585955e-04 | 3.181 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 6.901452e-04 | 3.161 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 7.501150e-04 | 3.125 | 1 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 7.278091e-04 | 3.138 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 7.576878e-04 | 3.121 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 7.576878e-04 | 3.121 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 8.109664e-04 | 3.091 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 8.337868e-04 | 3.079 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 8.208547e-04 | 3.086 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 8.365774e-04 | 3.077 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 9.100026e-04 | 3.041 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 1.013654e-03 | 2.994 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 1.026737e-03 | 2.989 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 1.091321e-03 | 2.962 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 1.207229e-03 | 2.918 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 1.419514e-03 | 2.848 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 1.419514e-03 | 2.848 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 1.419514e-03 | 2.848 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 1.419514e-03 | 2.848 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 1.474771e-03 | 2.831 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 1.434252e-03 | 2.843 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 1.546171e-03 | 2.811 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 1.604139e-03 | 2.795 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 1.630838e-03 | 2.788 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 1.913128e-03 | 2.718 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 1.913128e-03 | 2.718 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 1.958920e-03 | 2.708 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 1.972264e-03 | 2.705 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 1.972264e-03 | 2.705 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 1.988272e-03 | 2.702 | 1 | 0 |
| Integrin signaling | R-HSA-354192 | 2.145422e-03 | 2.668 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 2.147518e-03 | 2.668 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 2.145422e-03 | 2.668 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 2.267014e-03 | 2.645 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 2.280249e-03 | 2.642 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 2.304468e-03 | 2.637 | 1 | 1 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 2.521780e-03 | 2.598 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 2.521780e-03 | 2.598 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 2.521780e-03 | 2.598 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 2.521780e-03 | 2.598 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 2.521780e-03 | 2.598 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 2.365911e-03 | 2.626 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 2.521780e-03 | 2.598 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 2.461534e-03 | 2.609 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 2.365911e-03 | 2.626 | 0 | 0 |
| Protein folding | R-HSA-391251 | 2.801527e-03 | 2.553 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 2.901448e-03 | 2.537 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 2.967006e-03 | 2.528 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 2.996476e-03 | 2.523 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 2.804674e-03 | 2.552 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 2.801527e-03 | 2.553 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 3.033962e-03 | 2.518 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 2.967006e-03 | 2.528 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 3.162848e-03 | 2.500 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 3.180908e-03 | 2.497 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 3.323636e-03 | 2.478 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 3.349961e-03 | 2.475 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 3.547960e-03 | 2.450 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 3.655801e-03 | 2.437 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 3.655801e-03 | 2.437 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 3.738038e-03 | 2.427 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 4.341530e-03 | 2.362 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 4.049535e-03 | 2.393 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 4.239011e-03 | 2.373 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 3.986762e-03 | 2.399 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 4.560141e-03 | 2.341 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 4.851686e-03 | 2.314 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 5.065095e-03 | 2.295 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 5.120738e-03 | 2.291 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 5.182321e-03 | 2.285 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 5.182321e-03 | 2.285 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 5.182321e-03 | 2.285 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 5.287228e-03 | 2.277 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 5.391151e-03 | 2.268 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 5.391151e-03 | 2.268 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 6.074961e-03 | 2.216 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 6.074961e-03 | 2.216 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 5.777010e-03 | 2.238 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 5.522107e-03 | 2.258 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 5.730603e-03 | 2.242 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 6.074961e-03 | 2.216 | 0 | 0 |
| Activation, translocation and oligomerization of BAX | R-HSA-114294 | 6.083973e-03 | 2.216 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 6.083973e-03 | 2.216 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 6.552669e-03 | 2.184 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 6.698584e-03 | 2.174 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 7.010836e-03 | 2.154 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 7.102165e-03 | 2.149 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 7.152458e-03 | 2.146 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 7.270739e-03 | 2.138 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 7.402250e-03 | 2.131 | 0 | 0 |
| NFE2L2 regulating TCA cycle genes | R-HSA-9818025 | 7.973705e-03 | 2.098 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 8.014157e-03 | 2.096 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 9.710977e-03 | 2.013 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 9.710977e-03 | 2.013 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 9.124283e-03 | 2.040 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 9.143184e-03 | 2.039 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 9.908603e-03 | 2.004 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 1.018011e-02 | 1.992 | 1 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 1.120429e-02 | 1.951 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 1.120429e-02 | 1.951 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 1.135357e-02 | 1.945 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 1.141388e-02 | 1.943 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 1.151940e-02 | 1.939 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 1.151940e-02 | 1.939 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 1.165874e-02 | 1.933 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 1.212420e-02 | 1.916 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 1.223145e-02 | 1.913 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 1.286210e-02 | 1.891 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 1.310388e-02 | 1.883 | 0 | 0 |
| Defective Base Excision Repair Associated with OGG1 | R-HSA-9656249 | 1.318280e-02 | 1.880 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 1.318280e-02 | 1.880 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.319646e-02 | 1.880 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 1.425532e-02 | 1.846 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 1.426699e-02 | 1.846 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 1.426699e-02 | 1.846 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 1.426699e-02 | 1.846 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 1.558635e-02 | 1.807 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 1.558635e-02 | 1.807 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.652209e-02 | 1.782 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 1.558635e-02 | 1.807 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 1.528132e-02 | 1.816 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 1.666803e-02 | 1.778 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 1.691962e-02 | 1.772 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 1.695411e-02 | 1.771 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 1.739717e-02 | 1.760 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 1.739717e-02 | 1.760 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.747646e-02 | 1.758 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.766572e-02 | 1.753 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 1.774731e-02 | 1.751 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 1.802839e-02 | 1.744 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 1.820582e-02 | 1.740 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 1.925531e-02 | 1.715 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 2.035165e-02 | 1.691 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 2.050820e-02 | 1.688 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 2.050820e-02 | 1.688 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 2.080142e-02 | 1.682 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 2.257371e-02 | 1.646 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 2.257371e-02 | 1.646 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 2.257371e-02 | 1.646 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 2.346855e-02 | 1.630 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 2.149243e-02 | 1.668 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 2.485931e-02 | 1.605 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 2.485931e-02 | 1.605 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 2.346855e-02 | 1.630 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 2.190218e-02 | 1.660 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 2.323266e-02 | 1.634 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 2.241092e-02 | 1.650 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 2.229661e-02 | 1.652 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 2.518518e-02 | 1.599 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 2.618627e-02 | 1.582 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 2.618627e-02 | 1.582 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 2.646696e-02 | 1.577 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.646696e-02 | 1.577 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 2.698264e-02 | 1.569 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 2.698264e-02 | 1.569 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 2.859721e-02 | 1.544 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 2.921169e-02 | 1.534 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 2.921169e-02 | 1.534 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 2.921169e-02 | 1.534 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 2.955940e-02 | 1.529 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 2.966341e-02 | 1.528 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 3.397985e-02 | 1.469 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 3.397985e-02 | 1.469 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 3.255491e-02 | 1.487 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 3.255491e-02 | 1.487 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 3.348929e-02 | 1.475 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 3.348929e-02 | 1.475 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 3.261860e-02 | 1.487 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 3.261860e-02 | 1.487 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 3.255491e-02 | 1.487 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 3.591308e-02 | 1.445 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 3.348929e-02 | 1.475 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 3.304689e-02 | 1.481 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 3.519914e-02 | 1.453 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 3.229708e-02 | 1.491 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 3.460774e-02 | 1.461 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 3.162630e-02 | 1.500 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 3.460774e-02 | 1.461 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 3.623740e-02 | 1.441 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 3.708340e-02 | 1.431 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 3.876837e-02 | 1.412 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 3.892095e-02 | 1.410 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 3.919097e-02 | 1.407 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 3.919097e-02 | 1.407 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 3.933618e-02 | 1.405 | 1 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 3.979569e-02 | 1.400 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 3.979569e-02 | 1.400 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 3.979569e-02 | 1.400 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 3.979569e-02 | 1.400 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 4.026141e-02 | 1.395 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 4.026141e-02 | 1.395 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 4.075616e-02 | 1.390 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 4.077952e-02 | 1.390 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 4.150882e-02 | 1.382 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 4.322121e-02 | 1.364 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 4.482331e-02 | 1.348 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 4.482331e-02 | 1.348 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 4.482331e-02 | 1.348 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 4.482331e-02 | 1.348 | 0 | 0 |
| Defective OGG1 Localization | R-HSA-9657050 | 5.570843e-02 | 1.254 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p14ARF Defects | R-HSA-9646303 | 5.570843e-02 | 1.254 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects | R-HSA-9646304 | 5.570843e-02 | 1.254 | 0 | 0 |
| Defective OGG1 Substrate Binding | R-HSA-9656255 | 5.570843e-02 | 1.254 | 0 | 0 |
| Deletions in the AMER1 gene destabilize the destruction complex | R-HSA-5467343 | 5.570843e-02 | 1.254 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 4.714802e-02 | 1.327 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 4.714802e-02 | 1.327 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 4.714802e-02 | 1.327 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 4.770166e-02 | 1.321 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 4.770166e-02 | 1.321 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 5.631526e-02 | 1.249 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 5.088395e-02 | 1.293 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 5.088395e-02 | 1.293 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 5.125284e-02 | 1.290 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 4.728754e-02 | 1.325 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 4.846120e-02 | 1.315 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 4.728754e-02 | 1.325 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 5.631526e-02 | 1.249 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 5.631526e-02 | 1.249 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 5.498157e-02 | 1.260 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 4.774357e-02 | 1.321 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 5.152117e-02 | 1.288 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 5.631526e-02 | 1.249 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 4.811427e-02 | 1.318 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 4.878310e-02 | 1.312 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 5.301249e-02 | 1.276 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 4.796876e-02 | 1.319 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 4.770166e-02 | 1.321 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 5.737008e-02 | 1.241 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 5.737008e-02 | 1.241 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 5.737008e-02 | 1.241 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 5.737008e-02 | 1.241 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 5.737008e-02 | 1.241 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 5.835289e-02 | 1.234 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 5.863336e-02 | 1.232 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 5.863336e-02 | 1.232 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 5.879500e-02 | 1.231 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 6.000112e-02 | 1.222 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 6.184695e-02 | 1.209 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 6.184695e-02 | 1.209 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 6.184695e-02 | 1.209 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 6.184695e-02 | 1.209 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 6.184695e-02 | 1.209 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 6.243473e-02 | 1.205 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 6.306819e-02 | 1.200 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 6.398946e-02 | 1.194 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 6.427694e-02 | 1.192 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 6.427694e-02 | 1.192 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 6.427694e-02 | 1.192 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 6.464783e-02 | 1.189 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 6.557030e-02 | 1.183 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 6.561078e-02 | 1.183 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 6.561078e-02 | 1.183 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 6.561078e-02 | 1.183 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 6.561078e-02 | 1.183 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 6.561078e-02 | 1.183 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 6.561078e-02 | 1.183 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 6.561078e-02 | 1.183 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 6.609322e-02 | 1.180 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 7.159792e-02 | 1.145 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 7.245453e-02 | 1.140 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 7.435470e-02 | 1.129 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 7.484219e-02 | 1.126 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 7.786560e-02 | 1.109 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 7.786560e-02 | 1.109 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 7.786560e-02 | 1.109 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 9.501168e-02 | 1.022 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 7.555887e-02 | 1.122 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 8.612726e-02 | 1.065 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 8.612726e-02 | 1.065 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 9.728142e-02 | 1.012 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 7.932472e-02 | 1.101 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 8.744753e-02 | 1.058 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 9.595511e-02 | 1.018 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 7.614448e-02 | 1.118 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 8.265739e-02 | 1.083 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 8.265739e-02 | 1.083 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 9.653383e-02 | 1.015 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 8.060946e-02 | 1.094 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 8.231351e-02 | 1.085 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 8.265739e-02 | 1.083 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 9.427907e-02 | 1.026 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 7.932472e-02 | 1.101 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 8.612726e-02 | 1.065 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 8.945544e-02 | 1.048 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 7.786560e-02 | 1.109 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 8.231351e-02 | 1.085 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 7.614448e-02 | 1.118 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 9.984577e-02 | 1.001 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 9.984577e-02 | 1.001 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 9.984577e-02 | 1.001 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 9.984577e-02 | 1.001 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 7.786560e-02 | 1.109 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 9.728142e-02 | 1.012 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 9.728142e-02 | 1.012 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 7.614448e-02 | 1.118 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 9.467977e-02 | 1.024 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 7.786560e-02 | 1.109 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 7.865015e-02 | 1.104 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 8.612726e-02 | 1.065 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 9.728142e-02 | 1.012 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 9.984577e-02 | 1.001 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 8.164590e-02 | 1.088 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 7.786560e-02 | 1.109 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 8.744753e-02 | 1.058 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 9.984577e-02 | 1.001 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 8.138254e-02 | 1.089 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 9.728142e-02 | 1.012 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 8.945544e-02 | 1.048 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 8.841555e-02 | 1.053 | 0 | 0 |
| Diseases of Base Excision Repair | R-HSA-9605308 | 7.786560e-02 | 1.109 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 9.501168e-02 | 1.022 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 7.786560e-02 | 1.109 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 9.991018e-02 | 1.000 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 1.013076e-01 | 0.994 | 0 | 0 |
| S Phase | R-HSA-69242 | 1.016637e-01 | 0.993 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 1.034425e-01 | 0.985 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 1.038870e-01 | 0.983 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 1.038870e-01 | 0.983 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 1.038870e-01 | 0.983 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 1.048350e-01 | 0.979 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 1.048350e-01 | 0.979 | 0 | 0 |
| Defective OGG1 Substrate Processing | R-HSA-9656256 | 1.083166e-01 | 0.965 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 1.083166e-01 | 0.965 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 1.083166e-01 | 0.965 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 1.083166e-01 | 0.965 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 1.083166e-01 | 0.965 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 1.083166e-01 | 0.965 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9630791 | 1.083166e-01 | 0.965 | 0 | 0 |
| Impaired BRCA2 binding to SEM1 (DSS1) | R-HSA-9763198 | 1.083166e-01 | 0.965 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 1.083166e-01 | 0.965 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function | R-HSA-9645722 | 1.083166e-01 | 0.965 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 1.083166e-01 | 0.965 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 1.083166e-01 | 0.965 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 1.083166e-01 | 0.965 | 0 | 0 |
| Impaired BRCA2 translocation to the nucleus | R-HSA-9709275 | 1.083166e-01 | 0.965 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9632697 | 1.083166e-01 | 0.965 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 1.579969e-01 | 0.801 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 1.579969e-01 | 0.801 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 1.579969e-01 | 0.801 | 0 | 0 |
| Defective VWF binding to collagen type I | R-HSA-9845622 | 1.579969e-01 | 0.801 | 0 | 0 |
| Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome | R-HSA-5678420 | 1.579969e-01 | 0.801 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 1.579969e-01 | 0.801 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 1.579969e-01 | 0.801 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 1.579969e-01 | 0.801 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 1.579969e-01 | 0.801 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 1.579969e-01 | 0.801 | 0 | 0 |
| XAV939 stabilizes AXIN | R-HSA-5545619 | 1.579969e-01 | 0.801 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 1.579969e-01 | 0.801 | 0 | 0 |
| Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) | R-HSA-5619039 | 1.579969e-01 | 0.801 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 1.131102e-01 | 0.946 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 1.131102e-01 | 0.946 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 1.131102e-01 | 0.946 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 1.131102e-01 | 0.946 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 1.131102e-01 | 0.946 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 1.320020e-01 | 0.879 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 1.320020e-01 | 0.879 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 1.320020e-01 | 0.879 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 1.515428e-01 | 0.819 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 1.515428e-01 | 0.819 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 1.515428e-01 | 0.819 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 1.515428e-01 | 0.819 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 1.515428e-01 | 0.819 | 1 | 1 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.089851e-01 | 0.963 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 1.338903e-01 | 0.873 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 1.470150e-01 | 0.833 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 1.140736e-01 | 0.943 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 1.335677e-01 | 0.874 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 1.275292e-01 | 0.894 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.359126e-01 | 0.867 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 1.128424e-01 | 0.948 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 1.340697e-01 | 0.873 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 1.340697e-01 | 0.873 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 1.415379e-01 | 0.849 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 1.543116e-01 | 0.812 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 1.543116e-01 | 0.812 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 1.437917e-01 | 0.842 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 1.089851e-01 | 0.963 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.436043e-01 | 0.843 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 1.140736e-01 | 0.943 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 1.212008e-01 | 0.916 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 1.131102e-01 | 0.946 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 1.515428e-01 | 0.819 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 1.089851e-01 | 0.963 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 1.142011e-01 | 0.942 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 1.470150e-01 | 0.833 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 1.335677e-01 | 0.874 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 1.437917e-01 | 0.842 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 1.255388e-01 | 0.901 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 1.141872e-01 | 0.942 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 1.131102e-01 | 0.946 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 1.320020e-01 | 0.879 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 1.236563e-01 | 0.908 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 1.338903e-01 | 0.873 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 1.230838e-01 | 0.910 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 1.230838e-01 | 0.910 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 1.230838e-01 | 0.910 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.515428e-01 | 0.819 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 1.162316e-01 | 0.935 | 0 | 0 |
| Activation and oligomerization of BAK protein | R-HSA-111452 | 1.083166e-01 | 0.965 | 0 | 0 |
| Nef mediated downregulation of CD28 cell surface expression | R-HSA-164939 | 1.579969e-01 | 0.801 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 1.128424e-01 | 0.948 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 1.436043e-01 | 0.843 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 1.298492e-01 | 0.887 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 1.445335e-01 | 0.840 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 1.360586e-01 | 0.866 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 1.437917e-01 | 0.842 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 1.543116e-01 | 0.812 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 1.140736e-01 | 0.943 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 1.530277e-01 | 0.815 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 1.579969e-01 | 0.801 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 1.131102e-01 | 0.946 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 1.320020e-01 | 0.879 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 1.515428e-01 | 0.819 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 1.470150e-01 | 0.833 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 1.437917e-01 | 0.842 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 1.437917e-01 | 0.842 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 1.298492e-01 | 0.887 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 1.097919e-01 | 0.959 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 1.515428e-01 | 0.819 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 1.515428e-01 | 0.819 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.445335e-01 | 0.840 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 1.515428e-01 | 0.819 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 1.140736e-01 | 0.943 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 1.515428e-01 | 0.819 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 1.087486e-01 | 0.964 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 1.515428e-01 | 0.819 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 1.470150e-01 | 0.833 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.438248e-01 | 0.842 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 1.055884e-01 | 0.976 | 0 | 0 |
| NTRK3 as a dependence receptor | R-HSA-9603505 | 1.579969e-01 | 0.801 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 1.131102e-01 | 0.946 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 1.089851e-01 | 0.963 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 1.175929e-01 | 0.930 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 1.175929e-01 | 0.930 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 1.359126e-01 | 0.867 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 1.275292e-01 | 0.894 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 1.515428e-01 | 0.819 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 1.236563e-01 | 0.908 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 1.340697e-01 | 0.873 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 1.317227e-01 | 0.880 | 1 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 1.250460e-01 | 0.903 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 1.470150e-01 | 0.833 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 1.605361e-01 | 0.794 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 1.605361e-01 | 0.794 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 1.605361e-01 | 0.794 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 1.647605e-01 | 0.783 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 1.650451e-01 | 0.782 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 1.695345e-01 | 0.771 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 1.695345e-01 | 0.771 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 2.049120e-01 | 0.688 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 2.049120e-01 | 0.688 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 2.049120e-01 | 0.688 | 0 | 0 |
| Enhanced cleavage of VWF variant by ADAMTS13 | R-HSA-9845619 | 2.049120e-01 | 0.688 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 2.049120e-01 | 0.688 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 2.049120e-01 | 0.688 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 2.049120e-01 | 0.688 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 2.049120e-01 | 0.688 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 2.049120e-01 | 0.688 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 2.049120e-01 | 0.688 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 2.049120e-01 | 0.688 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 2.049120e-01 | 0.688 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 2.049120e-01 | 0.688 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 2.049120e-01 | 0.688 | 0 | 0 |
| Defective VWF cleavage by ADAMTS13 variant | R-HSA-9845621 | 2.049120e-01 | 0.688 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 2.492158e-01 | 0.603 | 0 | 0 |
| Classical Kir channels | R-HSA-1296053 | 2.492158e-01 | 0.603 | 0 | 0 |
| Defective DPM1 causes DPM1-CDG | R-HSA-4717374 | 2.492158e-01 | 0.603 | 0 | 0 |
| Defective DPM3 causes DPM3-CDG | R-HSA-4719360 | 2.492158e-01 | 0.603 | 0 | 0 |
| Defective DPM2 causes DPM2-CDG | R-HSA-4719377 | 2.492158e-01 | 0.603 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 2.492158e-01 | 0.603 | 0 | 0 |
| Defective PNP disrupts phosphorolysis of (deoxy)guanosine and (deoxy)inosine | R-HSA-9735763 | 2.910535e-01 | 0.536 | 0 | 0 |
| Nucleotide catabolism defects | R-HSA-9735786 | 2.910535e-01 | 0.536 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 2.910535e-01 | 0.536 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 2.910535e-01 | 0.536 | 0 | 0 |
| Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate | R-HSA-2978092 | 2.910535e-01 | 0.536 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 1.716020e-01 | 0.765 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 1.716020e-01 | 0.765 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 1.716020e-01 | 0.765 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 1.716020e-01 | 0.765 | 0 | 0 |
| IRS activation | R-HSA-74713 | 3.305621e-01 | 0.481 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 3.305621e-01 | 0.481 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 3.305621e-01 | 0.481 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 3.305621e-01 | 0.481 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 3.305621e-01 | 0.481 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 3.305621e-01 | 0.481 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 2.128138e-01 | 0.672 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 2.337638e-01 | 0.631 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 2.337638e-01 | 0.631 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 1.744153e-01 | 0.758 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 1.886144e-01 | 0.724 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 1.886144e-01 | 0.724 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 2.030962e-01 | 0.692 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 2.030962e-01 | 0.692 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 2.178243e-01 | 0.662 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 2.969792e-01 | 0.527 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 2.327630e-01 | 0.633 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 2.327630e-01 | 0.633 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 1.990000e-01 | 0.701 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 2.478783e-01 | 0.606 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 3.179420e-01 | 0.498 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 3.179420e-01 | 0.498 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 3.179420e-01 | 0.498 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 3.387535e-01 | 0.470 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 3.387535e-01 | 0.470 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 3.387535e-01 | 0.470 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 2.007155e-01 | 0.697 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 1.732284e-01 | 0.761 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 2.939582e-01 | 0.532 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 2.939582e-01 | 0.532 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 2.939582e-01 | 0.532 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 2.939582e-01 | 0.532 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 1.900779e-01 | 0.721 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 1.900779e-01 | 0.721 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 1.987306e-01 | 0.702 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 3.094615e-01 | 0.509 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 3.094615e-01 | 0.509 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 3.094615e-01 | 0.509 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 3.094615e-01 | 0.509 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 3.094615e-01 | 0.509 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 2.718805e-01 | 0.566 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 2.844801e-01 | 0.546 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 2.844801e-01 | 0.546 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 2.629143e-01 | 0.580 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 3.405155e-01 | 0.468 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 3.405155e-01 | 0.468 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 2.737003e-01 | 0.563 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 3.099129e-01 | 0.509 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 3.099129e-01 | 0.509 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 3.099129e-01 | 0.509 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 3.227137e-01 | 0.491 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 2.270339e-01 | 0.644 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 3.355498e-01 | 0.474 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 2.821345e-01 | 0.550 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 2.581188e-01 | 0.588 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 2.660886e-01 | 0.575 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 3.314484e-01 | 0.480 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 2.845696e-01 | 0.546 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 2.845696e-01 | 0.546 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 2.724660e-01 | 0.565 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 2.050654e-01 | 0.688 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 2.844801e-01 | 0.546 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 2.548248e-01 | 0.594 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 3.249893e-01 | 0.488 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 3.405155e-01 | 0.468 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 2.548248e-01 | 0.594 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 2.844801e-01 | 0.546 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.721057e-01 | 0.764 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 3.001538e-01 | 0.523 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 1.716020e-01 | 0.765 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 2.178243e-01 | 0.662 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 2.718805e-01 | 0.566 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 2.844801e-01 | 0.546 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 2.660886e-01 | 0.575 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 3.231884e-01 | 0.491 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 2.107347e-01 | 0.676 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 2.478783e-01 | 0.606 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 3.405155e-01 | 0.468 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 3.065574e-01 | 0.513 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 2.969792e-01 | 0.527 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 2.327630e-01 | 0.633 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 2.844801e-01 | 0.546 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 1.761696e-01 | 0.754 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 1.874723e-01 | 0.727 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 2.910535e-01 | 0.536 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 1.716020e-01 | 0.765 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 1.920612e-01 | 0.717 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 3.305621e-01 | 0.481 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 2.548248e-01 | 0.594 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 2.759197e-01 | 0.559 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 3.387535e-01 | 0.470 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 2.844801e-01 | 0.546 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 2.844801e-01 | 0.546 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 3.387535e-01 | 0.470 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 2.969792e-01 | 0.527 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 1.990000e-01 | 0.701 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 2.785070e-01 | 0.555 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 3.387535e-01 | 0.470 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 2.955326e-01 | 0.529 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 1.874723e-01 | 0.727 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 2.631369e-01 | 0.580 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 2.629143e-01 | 0.580 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 3.099129e-01 | 0.509 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 3.016884e-01 | 0.520 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 2.226582e-01 | 0.652 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 2.918778e-01 | 0.535 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 2.915039e-01 | 0.535 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 2.226582e-01 | 0.652 | 0 | 0 |
| Neurophilin interactions with VEGF and VEGFR | R-HSA-194306 | 2.049120e-01 | 0.688 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 2.492158e-01 | 0.603 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 2.910535e-01 | 0.536 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 2.910535e-01 | 0.536 | 0 | 0 |
| ATP sensitive Potassium channels | R-HSA-1296025 | 2.910535e-01 | 0.536 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 3.305621e-01 | 0.481 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 2.128138e-01 | 0.672 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 2.107347e-01 | 0.676 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 3.387535e-01 | 0.470 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 3.399395e-01 | 0.469 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 1.874723e-01 | 0.727 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 1.874723e-01 | 0.727 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 1.716020e-01 | 0.765 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 1.744153e-01 | 0.758 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 2.272658e-01 | 0.643 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 2.904050e-01 | 0.537 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 2.904050e-01 | 0.537 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 2.904050e-01 | 0.537 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 2.208953e-01 | 0.656 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 1.723643e-01 | 0.764 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 3.305621e-01 | 0.481 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 2.969792e-01 | 0.527 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 3.249893e-01 | 0.488 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 2.861857e-01 | 0.543 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 2.716908e-01 | 0.566 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 1.716020e-01 | 0.765 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 2.108262e-01 | 0.676 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 2.797582e-01 | 0.553 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 1.795428e-01 | 0.746 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 2.478783e-01 | 0.606 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 2.337638e-01 | 0.631 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 2.194826e-01 | 0.659 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 3.065574e-01 | 0.513 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 2.066518e-01 | 0.685 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 2.492158e-01 | 0.603 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 2.492158e-01 | 0.603 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 2.910535e-01 | 0.536 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 1.920612e-01 | 0.717 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 3.305621e-01 | 0.481 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 2.128138e-01 | 0.672 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 2.759197e-01 | 0.559 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 2.969792e-01 | 0.527 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 3.179420e-01 | 0.498 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 1.795902e-01 | 0.746 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 2.629143e-01 | 0.580 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 1.983286e-01 | 0.703 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 2.413401e-01 | 0.617 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 3.296490e-01 | 0.482 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 3.179420e-01 | 0.498 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 1.795902e-01 | 0.746 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 2.694777e-01 | 0.569 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 3.115587e-01 | 0.506 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 2.694777e-01 | 0.569 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 2.329066e-01 | 0.633 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 2.030962e-01 | 0.692 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 3.214812e-01 | 0.493 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 3.094615e-01 | 0.509 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 3.314484e-01 | 0.480 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 2.492158e-01 | 0.603 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 2.724660e-01 | 0.565 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 2.858997e-01 | 0.544 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 3.387535e-01 | 0.470 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 2.164564e-01 | 0.665 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 2.492158e-01 | 0.603 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 2.910535e-01 | 0.536 | 0 | 0 |
| Regulation of HMOX1 expression and activity | R-HSA-9707587 | 2.910535e-01 | 0.536 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 3.305621e-01 | 0.481 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 3.305621e-01 | 0.481 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 3.305621e-01 | 0.481 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 2.548248e-01 | 0.594 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 2.631369e-01 | 0.580 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 3.387535e-01 | 0.470 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 2.075258e-01 | 0.683 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 2.986314e-01 | 0.525 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 1.974217e-01 | 0.705 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 2.365930e-01 | 0.626 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 2.844801e-01 | 0.546 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 2.271527e-01 | 0.644 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 3.069108e-01 | 0.513 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 1.931667e-01 | 0.714 | 0 | 0 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 3.305621e-01 | 0.481 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 2.969792e-01 | 0.527 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 2.865107e-01 | 0.543 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 2.346943e-01 | 0.629 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 2.063999e-01 | 0.685 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 3.065574e-01 | 0.513 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 2.629143e-01 | 0.580 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 2.400746e-01 | 0.620 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 1.920612e-01 | 0.717 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 2.759197e-01 | 0.559 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 3.305621e-01 | 0.481 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 3.305621e-01 | 0.481 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 3.249893e-01 | 0.488 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 2.593812e-01 | 0.586 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 2.107347e-01 | 0.676 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 1.832477e-01 | 0.737 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 2.865107e-01 | 0.543 | 1 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 2.270339e-01 | 0.644 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 3.456655e-01 | 0.461 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 3.484062e-01 | 0.458 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 3.484062e-01 | 0.458 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 3.505801e-01 | 0.455 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 3.511352e-01 | 0.455 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 3.520070e-01 | 0.453 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 3.548205e-01 | 0.450 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 3.548205e-01 | 0.450 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 3.548205e-01 | 0.450 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 3.560153e-01 | 0.449 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 3.560153e-01 | 0.449 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 3.560153e-01 | 0.449 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 3.560153e-01 | 0.449 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 3.593656e-01 | 0.444 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 3.593656e-01 | 0.444 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 3.593656e-01 | 0.444 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 3.593656e-01 | 0.444 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 3.593656e-01 | 0.444 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 3.612682e-01 | 0.442 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 3.612682e-01 | 0.442 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 3.612682e-01 | 0.442 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 3.623487e-01 | 0.441 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 3.678712e-01 | 0.434 | 0 | 0 |
| Plus-strand DNA synthesis | R-HSA-164525 | 3.678712e-01 | 0.434 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 3.678712e-01 | 0.434 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 3.678712e-01 | 0.434 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 3.678712e-01 | 0.434 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 3.678712e-01 | 0.434 | 0 | 0 |
| Synthesis of dolichyl-phosphate mannose | R-HSA-162699 | 3.678712e-01 | 0.434 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 3.678712e-01 | 0.434 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 3.678712e-01 | 0.434 | 0 | 0 |
| VEGF binds to VEGFR leading to receptor dimerization | R-HSA-195399 | 3.678712e-01 | 0.434 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 3.678712e-01 | 0.434 | 0 | 0 |
| VEGF ligand-receptor interactions | R-HSA-194313 | 3.678712e-01 | 0.434 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 3.678712e-01 | 0.434 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 3.678712e-01 | 0.434 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 3.678712e-01 | 0.434 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 3.678712e-01 | 0.434 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 3.689772e-01 | 0.433 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 3.704729e-01 | 0.431 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 3.707795e-01 | 0.431 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 3.714656e-01 | 0.430 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 3.716184e-01 | 0.430 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 3.735702e-01 | 0.428 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 3.735702e-01 | 0.428 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 3.735702e-01 | 0.428 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 3.741218e-01 | 0.427 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 3.741218e-01 | 0.427 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 3.756267e-01 | 0.425 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 3.787850e-01 | 0.422 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 3.787850e-01 | 0.422 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 3.797358e-01 | 0.421 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 3.797358e-01 | 0.421 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 3.797358e-01 | 0.421 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 3.817007e-01 | 0.418 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 3.817007e-01 | 0.418 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 3.830787e-01 | 0.417 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 3.868445e-01 | 0.412 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 3.868445e-01 | 0.412 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 3.868445e-01 | 0.412 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 3.868445e-01 | 0.412 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 3.869536e-01 | 0.412 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 3.916454e-01 | 0.407 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 3.917853e-01 | 0.407 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 3.960004e-01 | 0.402 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 3.997506e-01 | 0.398 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 3.998273e-01 | 0.398 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 3.998273e-01 | 0.398 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 3.998273e-01 | 0.398 | 0 | 0 |
| Crosslinking of collagen fibrils | R-HSA-2243919 | 3.998273e-01 | 0.398 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 3.998273e-01 | 0.398 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 3.998273e-01 | 0.398 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 3.998273e-01 | 0.398 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 4.018654e-01 | 0.396 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 4.021317e-01 | 0.396 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 4.021317e-01 | 0.396 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 4.021317e-01 | 0.396 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 4.031031e-01 | 0.395 | 0 | 0 |
| Uncoating of the HIV Virion | R-HSA-162585 | 4.031031e-01 | 0.395 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 4.031031e-01 | 0.395 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 4.031031e-01 | 0.395 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 4.031031e-01 | 0.395 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 4.031031e-01 | 0.395 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 4.031031e-01 | 0.395 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 4.031031e-01 | 0.395 | 0 | 0 |
| Leukotriene receptors | R-HSA-391906 | 4.031031e-01 | 0.395 | 0 | 0 |
| Lipid particle organization | R-HSA-8964572 | 4.031031e-01 | 0.395 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 4.064070e-01 | 0.391 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 4.071912e-01 | 0.390 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 4.125003e-01 | 0.385 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 4.151334e-01 | 0.382 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 4.173082e-01 | 0.380 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 4.173082e-01 | 0.380 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 4.196078e-01 | 0.377 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 4.196078e-01 | 0.377 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 4.196078e-01 | 0.377 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 4.196078e-01 | 0.377 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 4.196078e-01 | 0.377 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 4.218724e-01 | 0.375 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 4.223181e-01 | 0.374 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 4.243516e-01 | 0.372 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 4.251911e-01 | 0.371 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 4.259232e-01 | 0.371 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 4.323563e-01 | 0.364 | 1 | 1 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 4.352164e-01 | 0.361 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 4.363733e-01 | 0.360 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 4.363733e-01 | 0.360 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 4.363733e-01 | 0.360 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 4.363733e-01 | 0.360 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 4.363733e-01 | 0.360 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 4.363733e-01 | 0.360 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 4.363733e-01 | 0.360 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 4.363733e-01 | 0.360 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 4.363733e-01 | 0.360 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 4.363733e-01 | 0.360 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 4.378116e-01 | 0.359 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 4.390495e-01 | 0.357 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 4.390495e-01 | 0.357 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 4.390495e-01 | 0.357 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 4.420147e-01 | 0.355 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 4.420147e-01 | 0.355 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 4.438379e-01 | 0.353 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 4.472599e-01 | 0.349 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 4.472599e-01 | 0.349 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 4.472599e-01 | 0.349 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 4.472599e-01 | 0.349 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 4.503513e-01 | 0.346 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 4.503513e-01 | 0.346 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 4.515320e-01 | 0.345 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 4.581290e-01 | 0.339 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 4.581290e-01 | 0.339 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 4.605372e-01 | 0.337 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 4.605372e-01 | 0.337 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 4.610208e-01 | 0.336 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 4.619027e-01 | 0.335 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 4.620037e-01 | 0.335 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 4.620037e-01 | 0.335 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 4.620037e-01 | 0.335 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 4.620037e-01 | 0.335 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 4.620037e-01 | 0.335 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 4.620037e-01 | 0.335 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 4.625711e-01 | 0.335 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 4.625711e-01 | 0.335 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 4.625711e-01 | 0.335 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 4.627999e-01 | 0.335 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 4.669428e-01 | 0.331 | 0 | 0 |
| Reverse Transcription of HIV RNA | R-HSA-162589 | 4.677910e-01 | 0.330 | 0 | 0 |
| Minus-strand DNA synthesis | R-HSA-164516 | 4.677910e-01 | 0.330 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 4.677910e-01 | 0.330 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 4.677910e-01 | 0.330 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 4.677910e-01 | 0.330 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 4.677910e-01 | 0.330 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 4.677910e-01 | 0.330 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 4.677910e-01 | 0.330 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 4.677910e-01 | 0.330 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 4.677910e-01 | 0.330 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 4.701146e-01 | 0.328 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 4.701146e-01 | 0.328 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 4.711438e-01 | 0.327 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 4.765743e-01 | 0.322 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 4.768261e-01 | 0.322 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 4.768261e-01 | 0.322 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 4.768261e-01 | 0.322 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 4.768261e-01 | 0.322 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 4.769432e-01 | 0.322 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 4.791704e-01 | 0.320 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 4.804530e-01 | 0.318 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 4.843146e-01 | 0.315 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 4.873869e-01 | 0.312 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 4.881841e-01 | 0.311 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 4.909588e-01 | 0.309 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 4.951242e-01 | 0.305 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 4.951242e-01 | 0.305 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 4.951242e-01 | 0.305 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 4.971518e-01 | 0.304 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 4.971518e-01 | 0.304 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 4.974593e-01 | 0.303 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 4.974593e-01 | 0.303 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 4.974593e-01 | 0.303 | 0 | 0 |
| 5-Phosphoribose 1-diphosphate biosynthesis | R-HSA-73843 | 4.974593e-01 | 0.303 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 4.974593e-01 | 0.303 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 4.974593e-01 | 0.303 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 4.974593e-01 | 0.303 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 4.974593e-01 | 0.303 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 4.974593e-01 | 0.303 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 4.974593e-01 | 0.303 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 4.974593e-01 | 0.303 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 4.974593e-01 | 0.303 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 4.974593e-01 | 0.303 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 4.976707e-01 | 0.303 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 4.995079e-01 | 0.301 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 5.051461e-01 | 0.297 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 5.051461e-01 | 0.297 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 5.051461e-01 | 0.297 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 5.051461e-01 | 0.297 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 5.051461e-01 | 0.297 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 5.057435e-01 | 0.296 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 5.115032e-01 | 0.291 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 5.115032e-01 | 0.291 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 5.130098e-01 | 0.290 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 5.130098e-01 | 0.290 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 5.130098e-01 | 0.290 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 5.130098e-01 | 0.290 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 5.141397e-01 | 0.289 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 5.141397e-01 | 0.289 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 5.141397e-01 | 0.289 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 5.149340e-01 | 0.288 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 5.191257e-01 | 0.285 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 5.191257e-01 | 0.285 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 5.237413e-01 | 0.281 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 5.254753e-01 | 0.279 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 5.254753e-01 | 0.279 | 0 | 0 |
| TET1,2,3 and TDG demethylate DNA | R-HSA-5221030 | 5.254753e-01 | 0.279 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 5.254753e-01 | 0.279 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 5.254753e-01 | 0.279 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 5.254753e-01 | 0.279 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 5.254753e-01 | 0.279 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 5.254753e-01 | 0.279 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 5.254753e-01 | 0.279 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 5.295882e-01 | 0.276 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 5.298011e-01 | 0.276 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 5.304719e-01 | 0.275 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 5.304719e-01 | 0.275 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 5.304719e-01 | 0.275 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 5.304719e-01 | 0.275 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 5.328885e-01 | 0.273 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 5.328885e-01 | 0.273 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 5.328885e-01 | 0.273 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 5.350883e-01 | 0.272 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 5.392215e-01 | 0.268 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 5.414464e-01 | 0.266 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 5.414464e-01 | 0.266 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 5.464263e-01 | 0.262 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 5.466131e-01 | 0.262 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 5.466650e-01 | 0.262 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 5.475022e-01 | 0.262 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 5.475022e-01 | 0.262 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 5.475022e-01 | 0.262 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 5.519311e-01 | 0.258 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 5.519311e-01 | 0.258 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 5.519311e-01 | 0.258 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 5.519311e-01 | 0.258 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 5.519311e-01 | 0.258 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 5.519311e-01 | 0.258 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 5.519311e-01 | 0.258 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 5.519311e-01 | 0.258 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 5.537794e-01 | 0.257 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 5.551330e-01 | 0.256 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 5.578119e-01 | 0.254 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 5.580899e-01 | 0.253 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 5.597318e-01 | 0.252 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 5.597318e-01 | 0.252 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 5.640946e-01 | 0.249 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 5.640946e-01 | 0.249 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 5.668080e-01 | 0.247 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 5.669749e-01 | 0.246 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 5.669906e-01 | 0.246 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 5.676957e-01 | 0.246 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 5.679777e-01 | 0.246 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 5.693579e-01 | 0.245 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 5.693579e-01 | 0.245 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 5.727987e-01 | 0.242 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 5.758442e-01 | 0.240 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 5.769134e-01 | 0.239 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 5.769134e-01 | 0.239 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 5.769134e-01 | 0.239 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 5.769134e-01 | 0.239 | 0 | 0 |
| Scavenging by Class H Receptors | R-HSA-3000497 | 5.769134e-01 | 0.239 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 5.769134e-01 | 0.239 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 5.769134e-01 | 0.239 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 5.769134e-01 | 0.239 | 0 | 0 |
| Anchoring fibril formation | R-HSA-2214320 | 5.769134e-01 | 0.239 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 5.769134e-01 | 0.239 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 5.769134e-01 | 0.239 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 5.804642e-01 | 0.236 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 5.804642e-01 | 0.236 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 5.820222e-01 | 0.235 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 5.835269e-01 | 0.234 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 5.856215e-01 | 0.232 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 5.856215e-01 | 0.232 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 5.856215e-01 | 0.232 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 5.856215e-01 | 0.232 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 5.874434e-01 | 0.231 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 5.891411e-01 | 0.230 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 5.909986e-01 | 0.228 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 5.959510e-01 | 0.225 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 5.959510e-01 | 0.225 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 5.959510e-01 | 0.225 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 5.981958e-01 | 0.223 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 5.981958e-01 | 0.223 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 5.981958e-01 | 0.223 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 5.981958e-01 | 0.223 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 5.981958e-01 | 0.223 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 5.981958e-01 | 0.223 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 6.005042e-01 | 0.221 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 6.005042e-01 | 0.221 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 6.005042e-01 | 0.221 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 6.005042e-01 | 0.221 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 6.005042e-01 | 0.221 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 6.005042e-01 | 0.221 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 6.005042e-01 | 0.221 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 6.005042e-01 | 0.221 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 6.005042e-01 | 0.221 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 6.005042e-01 | 0.221 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 6.005042e-01 | 0.221 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 6.026716e-01 | 0.220 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 6.093382e-01 | 0.215 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 6.105175e-01 | 0.214 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 6.111958e-01 | 0.214 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 6.112121e-01 | 0.214 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 6.112121e-01 | 0.214 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 6.112121e-01 | 0.214 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 6.112121e-01 | 0.214 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 6.112121e-01 | 0.214 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 6.119808e-01 | 0.213 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 6.127713e-01 | 0.213 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 6.180150e-01 | 0.209 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 6.195877e-01 | 0.208 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 6.227810e-01 | 0.206 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 6.227810e-01 | 0.206 | 0 | 0 |
| Diseases of nucleotide metabolism | R-HSA-9735804 | 6.227810e-01 | 0.206 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 6.227810e-01 | 0.206 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 6.227810e-01 | 0.206 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 6.227810e-01 | 0.206 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 6.227810e-01 | 0.206 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 6.227810e-01 | 0.206 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 6.227810e-01 | 0.206 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 6.238786e-01 | 0.205 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 6.238786e-01 | 0.205 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 6.260289e-01 | 0.203 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 6.260289e-01 | 0.203 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 6.260289e-01 | 0.203 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 6.336240e-01 | 0.198 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 6.404036e-01 | 0.194 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 6.404036e-01 | 0.194 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 6.404036e-01 | 0.194 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 6.404036e-01 | 0.194 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 6.438169e-01 | 0.191 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 6.438169e-01 | 0.191 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 6.438169e-01 | 0.191 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 6.438169e-01 | 0.191 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 6.438169e-01 | 0.191 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 6.438169e-01 | 0.191 | 0 | 0 |
| Glycerophospholipid catabolism | R-HSA-6814848 | 6.438169e-01 | 0.191 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 6.438169e-01 | 0.191 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 6.438169e-01 | 0.191 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 6.438169e-01 | 0.191 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 6.459401e-01 | 0.190 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 6.459401e-01 | 0.190 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 6.543394e-01 | 0.184 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 6.543394e-01 | 0.184 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 6.572276e-01 | 0.182 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 6.630613e-01 | 0.178 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 6.630613e-01 | 0.178 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 6.636809e-01 | 0.178 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 6.636809e-01 | 0.178 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 6.636809e-01 | 0.178 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 6.636809e-01 | 0.178 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 6.636809e-01 | 0.178 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 6.636809e-01 | 0.178 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 6.636809e-01 | 0.178 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 6.636809e-01 | 0.178 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 6.636809e-01 | 0.178 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 6.640098e-01 | 0.178 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 6.640483e-01 | 0.178 | 0 | 0 |
| Disease | R-HSA-1643685 | 6.667408e-01 | 0.176 | 1 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 6.678406e-01 | 0.175 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 6.725673e-01 | 0.172 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 6.725673e-01 | 0.172 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 6.767424e-01 | 0.170 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 6.790179e-01 | 0.168 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 6.790179e-01 | 0.168 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 6.790179e-01 | 0.168 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 6.790179e-01 | 0.168 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 6.809122e-01 | 0.167 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 6.809122e-01 | 0.167 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 6.809122e-01 | 0.167 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 6.809122e-01 | 0.167 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 6.809122e-01 | 0.167 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 6.809122e-01 | 0.167 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 6.824382e-01 | 0.166 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 6.824382e-01 | 0.166 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 6.824382e-01 | 0.166 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 6.824382e-01 | 0.166 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 6.824382e-01 | 0.166 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 6.824382e-01 | 0.166 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 6.824382e-01 | 0.166 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 6.824382e-01 | 0.166 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 6.843973e-01 | 0.165 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 6.895211e-01 | 0.161 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 6.895211e-01 | 0.161 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 6.919330e-01 | 0.160 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 6.935601e-01 | 0.159 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 6.935601e-01 | 0.159 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 6.999619e-01 | 0.155 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 6.999619e-01 | 0.155 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 6.999619e-01 | 0.155 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 6.999619e-01 | 0.155 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 7.001504e-01 | 0.155 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 7.001504e-01 | 0.155 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 7.001504e-01 | 0.155 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 7.001504e-01 | 0.155 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 7.001504e-01 | 0.155 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 7.001504e-01 | 0.155 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 7.001504e-01 | 0.155 | 0 | 0 |
| Biosynthesis of maresin-like SPMs | R-HSA-9027307 | 7.001504e-01 | 0.155 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 7.057910e-01 | 0.151 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 7.077635e-01 | 0.150 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 7.097480e-01 | 0.149 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 7.097480e-01 | 0.149 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 7.168758e-01 | 0.145 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 7.168758e-01 | 0.145 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 7.168758e-01 | 0.145 | 1 | 1 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 7.168758e-01 | 0.145 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 7.168758e-01 | 0.145 | 0 | 0 |
| Metabolism of ingested H2SeO4 and H2SeO3 into H2Se | R-HSA-2408550 | 7.168758e-01 | 0.145 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 7.168758e-01 | 0.145 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 7.172865e-01 | 0.144 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 7.176120e-01 | 0.144 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 7.176120e-01 | 0.144 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 7.289460e-01 | 0.137 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 7.289460e-01 | 0.137 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 7.290307e-01 | 0.137 | 0 | 0 |
| Depurination | R-HSA-73927 | 7.290307e-01 | 0.137 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 7.326691e-01 | 0.135 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 7.326691e-01 | 0.135 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 7.326691e-01 | 0.135 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 7.326691e-01 | 0.135 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 7.326691e-01 | 0.135 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 7.332713e-01 | 0.135 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 7.332713e-01 | 0.135 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 7.400553e-01 | 0.131 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 7.400553e-01 | 0.131 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 7.400553e-01 | 0.131 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 7.432485e-01 | 0.129 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 7.471329e-01 | 0.127 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 7.475824e-01 | 0.126 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 7.475824e-01 | 0.126 | 0 | 0 |
| Pyrimidine biosynthesis | R-HSA-500753 | 7.475824e-01 | 0.126 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 7.475824e-01 | 0.126 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 7.475824e-01 | 0.126 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 7.475824e-01 | 0.126 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 7.475824e-01 | 0.126 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 7.475824e-01 | 0.126 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 7.475824e-01 | 0.126 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 7.475824e-01 | 0.126 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 7.475824e-01 | 0.126 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 7.503050e-01 | 0.125 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 7.506942e-01 | 0.125 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 7.506942e-01 | 0.125 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 7.506942e-01 | 0.125 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 7.506942e-01 | 0.125 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 7.558540e-01 | 0.122 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 7.572566e-01 | 0.121 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 7.572566e-01 | 0.121 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 7.609560e-01 | 0.119 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 7.609560e-01 | 0.119 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 7.609560e-01 | 0.119 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 7.616646e-01 | 0.118 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 7.616646e-01 | 0.118 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 7.616646e-01 | 0.118 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 7.616646e-01 | 0.118 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 7.625409e-01 | 0.118 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 7.648000e-01 | 0.116 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 7.708497e-01 | 0.113 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 7.720803e-01 | 0.112 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 7.749619e-01 | 0.111 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 7.749619e-01 | 0.111 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 7.749619e-01 | 0.111 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 7.749619e-01 | 0.111 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 7.749619e-01 | 0.111 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 7.749619e-01 | 0.111 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 7.749619e-01 | 0.111 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 7.803844e-01 | 0.108 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 7.803844e-01 | 0.108 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 7.861082e-01 | 0.105 | 0 | 0 |
| Eicosanoids | R-HSA-211979 | 7.875182e-01 | 0.104 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 7.875182e-01 | 0.104 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 7.875182e-01 | 0.104 | 0 | 0 |
| Miscellaneous substrates | R-HSA-211958 | 7.875182e-01 | 0.104 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 7.875182e-01 | 0.104 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 7.875182e-01 | 0.104 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 7.895694e-01 | 0.103 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 7.960669e-01 | 0.099 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 7.984140e-01 | 0.098 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 7.993745e-01 | 0.097 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 7.993745e-01 | 0.097 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 7.993745e-01 | 0.097 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 7.993745e-01 | 0.097 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 7.993745e-01 | 0.097 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 7.993745e-01 | 0.097 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 7.993745e-01 | 0.097 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 7.993745e-01 | 0.097 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 7.995043e-01 | 0.097 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 8.069276e-01 | 0.093 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 8.069276e-01 | 0.093 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 8.097110e-01 | 0.092 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 8.102685e-01 | 0.091 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 8.105699e-01 | 0.091 | 0 | 0 |
| Fatty acids | R-HSA-211935 | 8.105699e-01 | 0.091 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 8.105699e-01 | 0.091 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 8.105699e-01 | 0.091 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 8.105699e-01 | 0.091 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 8.120904e-01 | 0.090 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 8.136502e-01 | 0.090 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 8.151195e-01 | 0.089 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 8.151195e-01 | 0.089 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 8.151195e-01 | 0.089 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 8.181672e-01 | 0.087 | 0 | 0 |
| Immune System | R-HSA-168256 | 8.210306e-01 | 0.086 | 1 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 8.211413e-01 | 0.086 | 0 | 0 |
| Assembly of active LPL and LIPC lipase complexes | R-HSA-8963889 | 8.211413e-01 | 0.086 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 8.211413e-01 | 0.086 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 8.211413e-01 | 0.086 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 8.238010e-01 | 0.084 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 8.273962e-01 | 0.082 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 8.302527e-01 | 0.081 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 8.302527e-01 | 0.081 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 8.305758e-01 | 0.081 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 8.311233e-01 | 0.080 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 8.311233e-01 | 0.080 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 8.311233e-01 | 0.080 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 8.311233e-01 | 0.080 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 8.311233e-01 | 0.080 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 8.311233e-01 | 0.080 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 8.311233e-01 | 0.080 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 8.311233e-01 | 0.080 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 8.311233e-01 | 0.080 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 8.378588e-01 | 0.077 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 8.378588e-01 | 0.077 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 8.405488e-01 | 0.075 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 8.405488e-01 | 0.075 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 8.405488e-01 | 0.075 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 8.405488e-01 | 0.075 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 8.405488e-01 | 0.075 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 8.405488e-01 | 0.075 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 8.405488e-01 | 0.075 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 8.415228e-01 | 0.075 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 8.448573e-01 | 0.073 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 8.494487e-01 | 0.071 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 8.494487e-01 | 0.071 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 8.494487e-01 | 0.071 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 8.494487e-01 | 0.071 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 8.566200e-01 | 0.067 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 8.578525e-01 | 0.067 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 8.578525e-01 | 0.067 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 8.578525e-01 | 0.067 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 8.578525e-01 | 0.067 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 8.578525e-01 | 0.067 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 8.580367e-01 | 0.066 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 8.620785e-01 | 0.064 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 8.642353e-01 | 0.063 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 8.657875e-01 | 0.063 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 8.657875e-01 | 0.063 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 8.657875e-01 | 0.063 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 8.658549e-01 | 0.063 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 8.701849e-01 | 0.060 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 8.704362e-01 | 0.060 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 8.727792e-01 | 0.059 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 8.731534e-01 | 0.059 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 8.732801e-01 | 0.059 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 8.732801e-01 | 0.059 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 8.732801e-01 | 0.059 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 8.758939e-01 | 0.058 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 8.803549e-01 | 0.055 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 8.803549e-01 | 0.055 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 8.813705e-01 | 0.055 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 8.833577e-01 | 0.054 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 8.853750e-01 | 0.053 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 8.857329e-01 | 0.053 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 8.866230e-01 | 0.052 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 8.916592e-01 | 0.050 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 8.916592e-01 | 0.050 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 8.933426e-01 | 0.049 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 8.960998e-01 | 0.048 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 8.964869e-01 | 0.047 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 8.964869e-01 | 0.047 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 8.974261e-01 | 0.047 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 8.988324e-01 | 0.046 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 8.992983e-01 | 0.046 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 8.992983e-01 | 0.046 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 8.992983e-01 | 0.046 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 8.992983e-01 | 0.046 | 0 | 0 |
| Translation | R-HSA-72766 | 8.995912e-01 | 0.046 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.011138e-01 | 0.045 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 9.027578e-01 | 0.044 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 9.027578e-01 | 0.044 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 9.027578e-01 | 0.044 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 9.049218e-01 | 0.043 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 9.049218e-01 | 0.043 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.049218e-01 | 0.043 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 9.049218e-01 | 0.043 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 9.055470e-01 | 0.043 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 9.092226e-01 | 0.041 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 9.097940e-01 | 0.041 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 9.097940e-01 | 0.041 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 9.102316e-01 | 0.041 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 9.102316e-01 | 0.041 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.102316e-01 | 0.041 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 9.124693e-01 | 0.040 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 9.152452e-01 | 0.038 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 9.152452e-01 | 0.038 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 9.152452e-01 | 0.038 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.152452e-01 | 0.038 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.152452e-01 | 0.038 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 9.152452e-01 | 0.038 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 9.199790e-01 | 0.036 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 9.199790e-01 | 0.036 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 9.199790e-01 | 0.036 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.199790e-01 | 0.036 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.199790e-01 | 0.036 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.199790e-01 | 0.036 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 9.214854e-01 | 0.036 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 9.224556e-01 | 0.035 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 9.228223e-01 | 0.035 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 9.236700e-01 | 0.034 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 9.244445e-01 | 0.034 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 9.244487e-01 | 0.034 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.244487e-01 | 0.034 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.244487e-01 | 0.034 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 9.244487e-01 | 0.034 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 9.258072e-01 | 0.033 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 9.260853e-01 | 0.033 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.284704e-01 | 0.032 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 9.286690e-01 | 0.032 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.314227e-01 | 0.031 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.326538e-01 | 0.030 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 9.326538e-01 | 0.030 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.333163e-01 | 0.030 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.341930e-01 | 0.030 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.341930e-01 | 0.030 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 9.364162e-01 | 0.029 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.364162e-01 | 0.029 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.378562e-01 | 0.028 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 9.378562e-01 | 0.028 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.390482e-01 | 0.027 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 9.392128e-01 | 0.027 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.397704e-01 | 0.027 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 9.399687e-01 | 0.027 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 9.399687e-01 | 0.027 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 9.399687e-01 | 0.027 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.399687e-01 | 0.027 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.407163e-01 | 0.027 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.407163e-01 | 0.027 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 9.433229e-01 | 0.025 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 9.433229e-01 | 0.025 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 9.433229e-01 | 0.025 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 9.433229e-01 | 0.025 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.434510e-01 | 0.025 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.434510e-01 | 0.025 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 9.465583e-01 | 0.024 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.485645e-01 | 0.023 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.494800e-01 | 0.023 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 9.494800e-01 | 0.023 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.509529e-01 | 0.022 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 9.523032e-01 | 0.021 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 9.523032e-01 | 0.021 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 9.523032e-01 | 0.021 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.523032e-01 | 0.021 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.529028e-01 | 0.021 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.532178e-01 | 0.021 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 9.532352e-01 | 0.021 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.535159e-01 | 0.021 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.549689e-01 | 0.020 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 9.549689e-01 | 0.020 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 9.549689e-01 | 0.020 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.549689e-01 | 0.020 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 9.554158e-01 | 0.020 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 9.574857e-01 | 0.019 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.574857e-01 | 0.019 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.574990e-01 | 0.019 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.594057e-01 | 0.018 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.594887e-01 | 0.018 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.598620e-01 | 0.018 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 9.598620e-01 | 0.018 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.598620e-01 | 0.018 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 9.602718e-01 | 0.018 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 9.607772e-01 | 0.017 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 9.632035e-01 | 0.016 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 9.662239e-01 | 0.015 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.662239e-01 | 0.015 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.662239e-01 | 0.015 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 9.681123e-01 | 0.014 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 9.681686e-01 | 0.014 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.681686e-01 | 0.014 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.696227e-01 | 0.013 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 9.729651e-01 | 0.012 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 9.731677e-01 | 0.012 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.760848e-01 | 0.011 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.764002e-01 | 0.010 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.783925e-01 | 0.009 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.786827e-01 | 0.009 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 9.786852e-01 | 0.009 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.786852e-01 | 0.009 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.798774e-01 | 0.009 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.798774e-01 | 0.009 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.804722e-01 | 0.009 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.808041e-01 | 0.008 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.810030e-01 | 0.008 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.810030e-01 | 0.008 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 9.810030e-01 | 0.008 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 9.810030e-01 | 0.008 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.820657e-01 | 0.008 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.823066e-01 | 0.008 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.840163e-01 | 0.007 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 9.847484e-01 | 0.007 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 9.847868e-01 | 0.007 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.853698e-01 | 0.006 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.853698e-01 | 0.006 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.857549e-01 | 0.006 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.857842e-01 | 0.006 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.861907e-01 | 0.006 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 9.865521e-01 | 0.006 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.865521e-01 | 0.006 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.873046e-01 | 0.006 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.873046e-01 | 0.006 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 9.873046e-01 | 0.006 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.873665e-01 | 0.006 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.883648e-01 | 0.005 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.886859e-01 | 0.005 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.893192e-01 | 0.005 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 9.901753e-01 | 0.004 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.902662e-01 | 0.004 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.904815e-01 | 0.004 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 9.904815e-01 | 0.004 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.910252e-01 | 0.004 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.919156e-01 | 0.004 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.928640e-01 | 0.003 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.929528e-01 | 0.003 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.939970e-01 | 0.003 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.939970e-01 | 0.003 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.948470e-01 | 0.002 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.949544e-01 | 0.002 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.949544e-01 | 0.002 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 9.950614e-01 | 0.002 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.952612e-01 | 0.002 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 9.955002e-01 | 0.002 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.957523e-01 | 0.002 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.959903e-01 | 0.002 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.962854e-01 | 0.002 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.963064e-01 | 0.002 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.966273e-01 | 0.001 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.970427e-01 | 0.001 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.974723e-01 | 0.001 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.976608e-01 | 0.001 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.977722e-01 | 0.001 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.978727e-01 | 0.001 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.978741e-01 | 0.001 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 9.979661e-01 | 0.001 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.980552e-01 | 0.001 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.981058e-01 | 0.001 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.985806e-01 | 0.001 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.986094e-01 | 0.001 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.989181e-01 | 0.000 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 9.989962e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.990525e-01 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.990815e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.991559e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.992149e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.993252e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.993291e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.993882e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.994683e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.996241e-01 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.996652e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.997192e-01 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 9.997263e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.997356e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.997377e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.997892e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.997892e-01 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 9.998425e-01 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 9.998488e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.998553e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.998594e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.998673e-01 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 9.999062e-01 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 9.999165e-01 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 9.999352e-01 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 9.999443e-01 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.999544e-01 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 9.999583e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.999917e-01 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.999917e-01 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 9.999973e-01 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.999984e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.999993e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.999995e-01 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 9.999997e-01 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 9.999999e-01 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle | R-HSA-1640170 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 1.110223e-16 | 15.955 | 0 | 0 |
| M Phase | R-HSA-68886 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 1.110223e-16 | 15.955 | 1 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 1.110223e-16 | 15.955 | 1 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 1.110223e-16 | 15.955 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 9.992007e-16 | 15.000 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 9.992007e-16 | 15.000 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 9.992007e-16 | 15.000 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.110223e-15 | 14.955 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 5.995204e-15 | 14.222 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 2.164935e-14 | 13.665 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 1.898481e-13 | 12.722 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 4.377609e-13 | 12.359 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 1.682765e-12 | 11.774 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 7.153056e-12 | 11.146 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 7.886913e-12 | 11.103 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 8.419598e-12 | 11.075 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 1.034173e-11 | 10.985 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 1.933320e-11 | 10.714 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 2.016609e-11 | 10.695 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 2.262013e-11 | 10.646 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 5.442224e-11 | 10.264 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 5.821010e-11 | 10.235 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 1.167851e-10 | 9.933 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 1.692594e-10 | 9.771 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.860817e-10 | 9.730 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 2.514127e-10 | 9.600 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 2.738532e-10 | 9.562 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 3.122038e-10 | 9.506 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 3.263374e-10 | 9.486 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 4.415074e-10 | 9.355 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 5.751313e-10 | 9.240 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 7.572473e-10 | 9.121 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 7.253678e-10 | 9.139 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 7.275950e-10 | 9.138 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 8.462332e-10 | 9.073 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 8.462332e-10 | 9.073 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 9.436470e-10 | 9.025 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.086075e-09 | 8.964 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 1.339625e-09 | 8.873 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 1.652164e-09 | 8.782 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 1.554320e-09 | 8.808 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 1.664949e-09 | 8.779 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 1.664949e-09 | 8.779 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 2.224428e-09 | 8.653 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 2.355934e-09 | 8.628 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 2.386899e-09 | 8.622 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 2.994234e-09 | 8.524 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 3.920330e-09 | 8.407 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 4.744329e-09 | 8.324 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 1.096694e-08 | 7.960 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 1.192390e-08 | 7.924 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.307043e-08 | 7.884 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 1.460094e-08 | 7.836 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 1.416909e-08 | 7.849 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 1.781728e-08 | 7.749 | 1 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 1.938846e-08 | 7.712 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 2.404616e-08 | 7.619 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 3.032524e-08 | 7.518 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 3.685050e-08 | 7.434 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 3.748425e-08 | 7.426 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 4.593572e-08 | 7.338 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 6.279573e-08 | 7.202 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 6.555277e-08 | 7.183 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 7.886333e-08 | 7.103 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 7.920612e-08 | 7.101 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 8.550110e-08 | 7.068 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 8.800474e-08 | 7.055 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 1.038565e-07 | 6.984 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 1.137569e-07 | 6.944 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 1.331806e-07 | 6.876 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 1.331806e-07 | 6.876 | 1 | 1 |
| Signaling by ALK in cancer | R-HSA-9700206 | 1.331806e-07 | 6.876 | 1 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 1.517483e-07 | 6.819 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 1.517483e-07 | 6.819 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 1.580534e-07 | 6.801 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 1.938765e-07 | 6.712 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.937263e-07 | 6.713 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 2.024226e-07 | 6.694 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 2.101495e-07 | 6.677 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 2.157290e-07 | 6.666 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 2.161345e-07 | 6.665 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 2.261346e-07 | 6.646 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 2.988221e-07 | 6.525 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 3.303196e-07 | 6.481 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 3.482627e-07 | 6.458 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 3.482627e-07 | 6.458 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 3.621983e-07 | 6.441 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 3.879833e-07 | 6.411 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 4.025226e-07 | 6.395 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 5.219484e-07 | 6.282 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 6.950132e-07 | 6.158 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 7.079088e-07 | 6.150 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 8.284833e-07 | 6.082 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 9.076421e-07 | 6.042 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 1.035897e-06 | 5.985 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 1.035897e-06 | 5.985 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 1.129385e-06 | 5.947 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 1.228668e-06 | 5.911 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.336740e-06 | 5.874 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 1.596647e-06 | 5.797 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 1.681898e-06 | 5.774 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 1.825077e-06 | 5.739 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 1.825077e-06 | 5.739 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 1.894678e-06 | 5.722 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 3.199321e-06 | 5.495 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 3.086837e-06 | 5.510 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 3.274264e-06 | 5.485 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 3.304862e-06 | 5.481 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 3.311571e-06 | 5.480 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 3.620453e-06 | 5.441 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 4.700723e-06 | 5.328 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 4.700723e-06 | 5.328 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 5.417869e-06 | 5.266 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 5.417869e-06 | 5.266 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 6.486184e-06 | 5.188 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 6.543791e-06 | 5.184 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 7.476724e-06 | 5.126 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 7.620488e-06 | 5.118 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 7.978277e-06 | 5.098 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 9.015086e-06 | 5.045 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 9.480194e-06 | 5.023 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 1.093161e-05 | 4.961 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 1.099908e-05 | 4.959 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 1.176203e-05 | 4.930 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 1.255588e-05 | 4.901 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 1.511623e-05 | 4.821 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 1.630147e-05 | 4.788 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 1.653413e-05 | 4.782 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.547612e-05 | 4.810 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 1.653413e-05 | 4.782 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.714593e-05 | 4.766 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 1.797354e-05 | 4.745 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.801168e-05 | 4.744 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 1.901924e-05 | 4.721 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.943252e-05 | 4.711 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 2.085662e-05 | 4.681 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 2.277109e-05 | 4.643 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 2.342234e-05 | 4.630 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 2.374427e-05 | 4.624 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 2.549823e-05 | 4.593 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 2.634256e-05 | 4.579 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 2.707392e-05 | 4.567 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 2.858520e-05 | 4.544 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 2.873507e-05 | 4.542 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 2.979665e-05 | 4.526 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 3.873596e-05 | 4.412 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 4.085482e-05 | 4.389 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 4.085482e-05 | 4.389 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 4.402338e-05 | 4.356 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 5.297655e-05 | 4.276 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 5.307788e-05 | 4.275 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 6.034916e-05 | 4.219 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 6.562271e-05 | 4.183 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 6.677208e-05 | 4.175 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 6.942421e-05 | 4.158 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 7.176805e-05 | 4.144 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 8.371432e-05 | 4.077 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 8.385226e-05 | 4.076 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 8.566184e-05 | 4.067 | 0 | 0 |
| Translation | R-HSA-72766 | 1.092358e-04 | 3.962 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 1.245035e-04 | 3.905 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 1.335777e-04 | 3.874 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 1.363565e-04 | 3.865 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 1.432699e-04 | 3.844 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 1.463828e-04 | 3.835 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.574091e-04 | 3.803 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 1.577470e-04 | 3.802 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 1.577470e-04 | 3.802 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 1.847007e-04 | 3.734 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 1.847007e-04 | 3.734 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 1.859558e-04 | 3.731 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 1.903866e-04 | 3.720 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 1.983200e-04 | 3.703 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 2.000594e-04 | 3.699 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 2.015164e-04 | 3.696 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 2.040671e-04 | 3.690 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 2.144132e-04 | 3.669 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 2.171391e-04 | 3.663 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 2.303803e-04 | 3.638 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 2.181500e-04 | 3.661 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 2.314227e-04 | 3.636 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 2.413037e-04 | 3.617 | 0 | 0 |
| S Phase | R-HSA-69242 | 2.416604e-04 | 3.617 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 2.429985e-04 | 3.614 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 2.470485e-04 | 3.607 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 2.527553e-04 | 3.597 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 2.755962e-04 | 3.560 | 0 | 0 |
| Protein folding | R-HSA-391251 | 2.779132e-04 | 3.556 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 2.851933e-04 | 3.545 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 2.999770e-04 | 3.523 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 3.094476e-04 | 3.509 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 3.189250e-04 | 3.496 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 3.189250e-04 | 3.496 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 3.189250e-04 | 3.496 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 3.430522e-04 | 3.465 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 3.472459e-04 | 3.459 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 3.565966e-04 | 3.448 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 3.519086e-04 | 3.454 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 3.438097e-04 | 3.464 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 3.531654e-04 | 3.452 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 3.588186e-04 | 3.445 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 3.750661e-04 | 3.426 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 3.772220e-04 | 3.423 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 3.772220e-04 | 3.423 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 3.772220e-04 | 3.423 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 3.772220e-04 | 3.423 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 3.777162e-04 | 3.423 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 3.777162e-04 | 3.423 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 3.803834e-04 | 3.420 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 4.084354e-04 | 3.389 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 4.087336e-04 | 3.389 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 4.300811e-04 | 3.366 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 4.412966e-04 | 3.355 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 4.656600e-04 | 3.332 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 4.761305e-04 | 3.322 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 4.878230e-04 | 3.312 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 5.292466e-04 | 3.276 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 5.451609e-04 | 3.263 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 5.451609e-04 | 3.263 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 5.597099e-04 | 3.252 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 6.222452e-04 | 3.206 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 6.334732e-04 | 3.198 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 5.933057e-04 | 3.227 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 6.631165e-04 | 3.178 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 6.631165e-04 | 3.178 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 6.003192e-04 | 3.222 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 6.723347e-04 | 3.172 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 6.771651e-04 | 3.169 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 7.114570e-04 | 3.148 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 7.120209e-04 | 3.148 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 7.155986e-04 | 3.145 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 7.325475e-04 | 3.135 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 7.396733e-04 | 3.131 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 7.480950e-04 | 3.126 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 7.738969e-04 | 3.111 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 8.052807e-04 | 3.094 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 8.399471e-04 | 3.076 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 8.923804e-04 | 3.049 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 8.994456e-04 | 3.046 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 9.656359e-04 | 3.015 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 1.021726e-03 | 2.991 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 1.024585e-03 | 2.989 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.063340e-03 | 2.973 | 0 | 0 |
| Depurination | R-HSA-73927 | 1.110782e-03 | 2.954 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 1.141645e-03 | 2.942 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 1.150171e-03 | 2.939 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 1.152253e-03 | 2.938 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 1.211896e-03 | 2.917 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 1.246014e-03 | 2.904 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 1.364191e-03 | 2.865 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 1.372567e-03 | 2.862 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 1.372567e-03 | 2.862 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 1.466800e-03 | 2.834 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 1.596953e-03 | 2.797 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 1.427713e-03 | 2.845 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 1.401548e-03 | 2.853 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 1.631915e-03 | 2.787 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.684239e-03 | 2.774 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 1.684239e-03 | 2.774 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 1.751944e-03 | 2.756 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 1.751944e-03 | 2.756 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 1.751944e-03 | 2.756 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 1.836180e-03 | 2.736 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 1.836180e-03 | 2.736 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 1.844320e-03 | 2.734 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 1.885950e-03 | 2.724 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 1.993853e-03 | 2.700 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 1.993853e-03 | 2.700 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 2.052908e-03 | 2.688 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 2.066060e-03 | 2.685 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 2.125822e-03 | 2.672 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 2.255640e-03 | 2.647 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 2.255640e-03 | 2.647 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 2.379077e-03 | 2.624 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 2.379077e-03 | 2.624 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 2.413817e-03 | 2.617 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 2.435552e-03 | 2.613 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 2.482616e-03 | 2.605 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 2.531778e-03 | 2.597 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 2.590330e-03 | 2.587 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 2.590460e-03 | 2.587 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 2.659225e-03 | 2.575 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 2.761594e-03 | 2.559 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 3.040985e-03 | 2.517 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 3.040985e-03 | 2.517 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 3.040985e-03 | 2.517 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 3.320747e-03 | 2.479 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 2.844932e-03 | 2.546 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 2.935800e-03 | 2.532 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 3.062474e-03 | 2.514 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 2.955174e-03 | 2.529 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 3.320747e-03 | 2.479 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 2.908317e-03 | 2.536 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 3.040985e-03 | 2.517 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 3.208695e-03 | 2.494 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 3.208695e-03 | 2.494 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 3.208695e-03 | 2.494 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 2.992748e-03 | 2.524 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 2.992748e-03 | 2.524 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 3.342944e-03 | 2.476 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 3.473134e-03 | 2.459 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 3.490495e-03 | 2.457 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 3.570934e-03 | 2.447 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 3.585179e-03 | 2.445 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 3.585179e-03 | 2.445 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 3.769607e-03 | 2.424 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 4.004934e-03 | 2.397 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 4.004934e-03 | 2.397 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 4.008276e-03 | 2.397 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 4.008383e-03 | 2.397 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 4.008383e-03 | 2.397 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 4.081648e-03 | 2.389 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 4.261175e-03 | 2.370 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 4.261175e-03 | 2.370 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 4.293026e-03 | 2.367 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 4.395213e-03 | 2.357 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 4.488278e-03 | 2.348 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 4.644510e-03 | 2.333 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 4.644510e-03 | 2.333 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 4.770480e-03 | 2.321 | 1 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 4.786315e-03 | 2.320 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 4.938286e-03 | 2.306 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 5.129151e-03 | 2.290 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 5.137698e-03 | 2.289 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 5.137698e-03 | 2.289 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 5.137698e-03 | 2.289 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 5.196486e-03 | 2.284 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 5.423326e-03 | 2.266 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 5.423326e-03 | 2.266 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 5.423326e-03 | 2.266 | 1 | 1 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 5.423326e-03 | 2.266 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 5.480247e-03 | 2.261 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 5.480247e-03 | 2.261 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 6.370215e-03 | 2.196 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 6.370215e-03 | 2.196 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 5.951174e-03 | 2.225 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 6.134244e-03 | 2.212 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 5.936645e-03 | 2.226 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 6.953899e-03 | 2.158 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 6.921752e-03 | 2.160 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 6.921752e-03 | 2.160 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 6.921752e-03 | 2.160 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 6.167971e-03 | 2.210 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 6.370215e-03 | 2.196 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 6.662478e-03 | 2.176 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 6.263054e-03 | 2.203 | 1 | 1 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 6.134244e-03 | 2.212 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 6.167971e-03 | 2.210 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 5.994526e-03 | 2.222 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 5.601437e-03 | 2.252 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 6.167971e-03 | 2.210 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 5.997893e-03 | 2.222 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 6.894103e-03 | 2.162 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 6.339003e-03 | 2.198 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 6.932690e-03 | 2.159 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 6.212485e-03 | 2.207 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 7.062724e-03 | 2.151 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 7.186523e-03 | 2.143 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 7.186523e-03 | 2.143 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 7.193837e-03 | 2.143 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 7.356293e-03 | 2.133 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 7.377736e-03 | 2.132 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 7.406770e-03 | 2.130 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 7.406770e-03 | 2.130 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 7.567606e-03 | 2.121 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 7.717647e-03 | 2.113 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 7.726107e-03 | 2.112 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 7.726107e-03 | 2.112 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 7.793337e-03 | 2.108 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 7.870520e-03 | 2.104 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 8.202425e-03 | 2.086 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 8.408470e-03 | 2.075 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 8.408470e-03 | 2.075 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 8.448947e-03 | 2.073 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 8.508994e-03 | 2.070 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 8.646325e-03 | 2.063 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 8.718623e-03 | 2.060 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 8.877797e-03 | 2.052 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 8.877797e-03 | 2.052 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 8.902556e-03 | 2.050 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 8.902556e-03 | 2.050 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 9.077594e-03 | 2.042 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 9.116438e-03 | 2.040 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 9.871050e-03 | 2.006 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 1.033122e-02 | 1.986 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.033122e-02 | 1.986 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 1.060434e-02 | 1.975 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 1.070295e-02 | 1.970 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 1.076936e-02 | 1.968 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 1.086376e-02 | 1.964 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 1.102608e-02 | 1.958 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 1.147448e-02 | 1.940 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 1.147448e-02 | 1.940 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 1.170457e-02 | 1.932 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 1.261036e-02 | 1.899 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 1.288182e-02 | 1.890 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 1.290230e-02 | 1.889 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 1.606705e-02 | 1.794 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 1.606705e-02 | 1.794 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 1.606705e-02 | 1.794 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 1.606705e-02 | 1.794 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 1.606705e-02 | 1.794 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 1.606705e-02 | 1.794 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 1.606705e-02 | 1.794 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 1.606705e-02 | 1.794 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 1.606705e-02 | 1.794 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 1.606705e-02 | 1.794 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 1.606705e-02 | 1.794 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 1.606705e-02 | 1.794 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 1.606705e-02 | 1.794 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 1.408114e-02 | 1.851 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 1.562289e-02 | 1.806 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 1.562289e-02 | 1.806 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 1.498502e-02 | 1.824 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.352290e-02 | 1.869 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 1.546256e-02 | 1.811 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 1.467957e-02 | 1.833 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.401589e-02 | 1.853 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 1.626181e-02 | 1.789 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 1.425939e-02 | 1.846 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 1.467957e-02 | 1.833 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.352290e-02 | 1.869 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 1.550839e-02 | 1.809 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 1.401589e-02 | 1.853 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 1.401589e-02 | 1.853 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 1.334380e-02 | 1.875 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 1.408114e-02 | 1.851 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 1.537092e-02 | 1.813 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 1.736529e-02 | 1.760 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 1.352290e-02 | 1.869 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 1.502599e-02 | 1.823 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 1.527494e-02 | 1.816 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 1.488690e-02 | 1.827 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 1.343866e-02 | 1.872 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 1.562289e-02 | 1.806 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 1.488690e-02 | 1.827 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 1.401589e-02 | 1.853 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 1.742306e-02 | 1.759 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 1.847860e-02 | 1.733 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 1.876217e-02 | 1.727 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 1.940785e-02 | 1.712 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 1.983523e-02 | 1.703 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 1.983523e-02 | 1.703 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 1.983523e-02 | 1.703 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 1.987327e-02 | 1.702 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 1.990609e-02 | 1.701 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 1.990609e-02 | 1.701 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 1.999551e-02 | 1.699 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 1.999551e-02 | 1.699 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 2.072932e-02 | 1.683 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 2.081564e-02 | 1.682 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 2.081564e-02 | 1.682 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 2.100135e-02 | 1.678 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 2.100135e-02 | 1.678 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 2.100135e-02 | 1.678 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 2.148707e-02 | 1.668 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 2.172528e-02 | 1.663 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 2.172528e-02 | 1.663 | 0 | 0 |
| Maturation of protein E | R-HSA-9683683 | 2.172528e-02 | 1.663 | 0 | 0 |
| Maturation of protein E | R-HSA-9694493 | 2.172528e-02 | 1.663 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 2.175177e-02 | 1.663 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 2.175177e-02 | 1.663 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 2.175369e-02 | 1.662 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 2.191867e-02 | 1.659 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 2.191867e-02 | 1.659 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 2.191867e-02 | 1.659 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 2.191867e-02 | 1.659 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 2.192540e-02 | 1.659 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 2.265080e-02 | 1.645 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 2.265080e-02 | 1.645 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 2.265080e-02 | 1.645 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 2.278564e-02 | 1.642 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 2.298699e-02 | 1.639 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 2.298699e-02 | 1.639 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 2.298699e-02 | 1.639 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 2.298699e-02 | 1.639 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 2.444291e-02 | 1.612 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 2.454011e-02 | 1.610 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 2.454011e-02 | 1.610 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 2.454011e-02 | 1.610 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 2.518900e-02 | 1.599 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 2.565501e-02 | 1.591 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 2.577198e-02 | 1.589 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 2.577198e-02 | 1.589 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 2.577198e-02 | 1.589 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 2.640545e-02 | 1.578 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 2.640545e-02 | 1.578 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 2.640545e-02 | 1.578 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 2.640545e-02 | 1.578 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 2.723812e-02 | 1.565 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 2.723812e-02 | 1.565 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 2.744542e-02 | 1.562 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 2.744542e-02 | 1.562 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 2.744542e-02 | 1.562 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 2.791094e-02 | 1.554 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 2.827698e-02 | 1.549 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 2.827698e-02 | 1.549 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 2.827698e-02 | 1.549 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 2.863055e-02 | 1.543 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 2.901128e-02 | 1.537 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 2.926047e-02 | 1.534 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 2.926047e-02 | 1.534 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 3.007927e-02 | 1.522 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 3.018001e-02 | 1.520 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 3.148955e-02 | 1.502 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 3.168858e-02 | 1.499 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 3.168858e-02 | 1.499 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 3.251109e-02 | 1.488 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 3.251109e-02 | 1.488 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 3.259259e-02 | 1.487 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 3.337238e-02 | 1.477 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 3.367222e-02 | 1.473 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 3.432828e-02 | 1.464 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 3.487164e-02 | 1.458 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 3.487164e-02 | 1.458 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 3.487164e-02 | 1.458 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 3.531864e-02 | 1.452 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 3.534801e-02 | 1.452 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 3.549846e-02 | 1.450 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 3.701825e-02 | 1.432 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 3.701825e-02 | 1.432 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 3.701825e-02 | 1.432 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 3.701825e-02 | 1.432 | 0 | 0 |
| Kinesins | R-HSA-983189 | 3.701825e-02 | 1.432 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 3.701825e-02 | 1.432 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 3.714162e-02 | 1.430 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 3.732684e-02 | 1.428 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 3.849843e-02 | 1.415 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 4.003164e-02 | 1.398 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 4.005273e-02 | 1.397 | 1 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 4.017142e-02 | 1.396 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 4.017142e-02 | 1.396 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 4.024755e-02 | 1.395 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 4.045721e-02 | 1.393 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 4.045721e-02 | 1.393 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 4.045721e-02 | 1.393 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 4.045721e-02 | 1.393 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 4.069813e-02 | 1.390 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 4.104726e-02 | 1.387 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 4.116345e-02 | 1.385 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 5.920142e-02 | 1.228 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 4.490253e-02 | 1.348 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 4.490253e-02 | 1.348 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 4.490253e-02 | 1.348 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 4.490253e-02 | 1.348 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 4.345333e-02 | 1.362 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 4.345333e-02 | 1.362 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 4.870191e-02 | 1.312 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 6.070809e-02 | 1.217 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 6.070809e-02 | 1.217 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 4.953306e-02 | 1.305 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 5.976380e-02 | 1.224 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 4.313263e-02 | 1.365 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 4.977805e-02 | 1.303 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 6.192774e-02 | 1.208 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 6.192774e-02 | 1.208 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 4.599859e-02 | 1.337 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 5.237053e-02 | 1.281 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 4.917452e-02 | 1.308 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 6.120803e-02 | 1.213 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 5.538196e-02 | 1.257 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 6.129675e-02 | 1.213 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 6.129675e-02 | 1.213 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 6.099627e-02 | 1.215 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 6.099627e-02 | 1.215 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 4.927553e-02 | 1.307 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 4.502705e-02 | 1.347 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 4.977805e-02 | 1.303 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 5.379857e-02 | 1.269 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 5.535050e-02 | 1.257 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 5.706429e-02 | 1.244 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 4.917452e-02 | 1.308 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 6.192774e-02 | 1.208 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 5.930182e-02 | 1.227 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 5.453019e-02 | 1.263 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 4.381093e-02 | 1.358 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 5.402325e-02 | 1.267 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 4.986651e-02 | 1.302 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 4.603993e-02 | 1.337 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 5.237053e-02 | 1.281 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 6.136485e-02 | 1.212 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 5.920142e-02 | 1.228 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 4.599859e-02 | 1.337 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 5.237053e-02 | 1.281 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 5.237053e-02 | 1.281 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 5.402325e-02 | 1.267 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 4.381093e-02 | 1.358 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 5.238257e-02 | 1.281 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 4.739045e-02 | 1.324 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 4.402953e-02 | 1.356 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 4.345333e-02 | 1.362 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 4.870191e-02 | 1.312 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 4.541782e-02 | 1.343 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 5.317917e-02 | 1.274 | 1 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 4.991662e-02 | 1.302 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 4.870191e-02 | 1.312 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 5.507801e-02 | 1.259 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 5.237053e-02 | 1.281 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 5.496999e-02 | 1.260 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 5.706429e-02 | 1.244 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 5.930182e-02 | 1.227 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 4.953306e-02 | 1.305 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 5.763167e-02 | 1.239 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 6.227171e-02 | 1.206 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 6.369611e-02 | 1.196 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 6.495376e-02 | 1.187 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 6.495376e-02 | 1.187 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 6.495376e-02 | 1.187 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 6.495376e-02 | 1.187 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 6.495376e-02 | 1.187 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 6.495376e-02 | 1.187 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 6.500527e-02 | 1.187 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 6.676303e-02 | 1.175 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 6.676303e-02 | 1.175 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 6.676303e-02 | 1.175 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 6.680403e-02 | 1.175 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 6.680403e-02 | 1.175 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 6.697681e-02 | 1.174 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 6.768488e-02 | 1.170 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 6.768488e-02 | 1.170 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 6.789758e-02 | 1.168 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 7.108864e-02 | 1.148 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 7.108864e-02 | 1.148 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 7.108864e-02 | 1.148 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 7.115992e-02 | 1.148 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 7.282643e-02 | 1.138 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 7.333402e-02 | 1.135 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 7.361069e-02 | 1.133 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 7.361069e-02 | 1.133 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 7.361069e-02 | 1.133 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 7.398240e-02 | 1.131 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 7.398240e-02 | 1.131 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 7.398240e-02 | 1.131 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 7.398240e-02 | 1.131 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 7.424199e-02 | 1.129 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 7.424199e-02 | 1.129 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 7.435525e-02 | 1.129 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 7.476605e-02 | 1.126 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 7.528066e-02 | 1.123 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 7.742555e-02 | 1.111 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 7.742555e-02 | 1.111 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 7.843022e-02 | 1.106 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 8.103169e-02 | 1.091 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 8.103169e-02 | 1.091 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 8.151063e-02 | 1.089 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 8.210577e-02 | 1.086 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 8.355176e-02 | 1.078 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 8.371749e-02 | 1.077 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 8.371749e-02 | 1.077 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 8.371749e-02 | 1.077 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 8.371749e-02 | 1.077 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 8.371749e-02 | 1.077 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 8.371749e-02 | 1.077 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 8.371749e-02 | 1.077 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 8.838723e-02 | 1.054 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 8.838723e-02 | 1.054 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 8.838723e-02 | 1.054 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 8.838723e-02 | 1.054 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 8.838723e-02 | 1.054 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 8.838723e-02 | 1.054 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 8.849968e-02 | 1.053 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 8.902328e-02 | 1.050 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 8.902328e-02 | 1.050 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 8.927531e-02 | 1.049 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 8.927531e-02 | 1.049 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 8.927531e-02 | 1.049 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 8.964047e-02 | 1.047 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 9.073602e-02 | 1.042 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 9.202783e-02 | 1.036 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 9.241450e-02 | 1.034 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 9.241450e-02 | 1.034 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 9.344011e-02 | 1.029 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 9.464657e-02 | 1.024 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 9.681835e-02 | 1.014 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 9.681835e-02 | 1.014 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 9.681835e-02 | 1.014 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 9.681835e-02 | 1.014 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 9.681835e-02 | 1.014 | 0 | 0 |
| Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK) | R-HSA-1299308 | 9.681835e-02 | 1.014 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 9.720249e-02 | 1.012 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 9.741880e-02 | 1.011 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 9.741880e-02 | 1.011 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 9.805110e-02 | 1.009 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 9.928236e-02 | 1.003 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 9.963302e-02 | 1.002 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 1.011818e-01 | 0.995 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 1.015453e-01 | 0.993 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 1.015453e-01 | 0.993 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 1.015453e-01 | 0.993 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 1.015453e-01 | 0.993 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 1.026421e-01 | 0.989 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 1.032566e-01 | 0.986 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 1.032566e-01 | 0.986 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 1.057573e-01 | 0.976 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 1.057573e-01 | 0.976 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 1.057573e-01 | 0.976 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 1.057573e-01 | 0.976 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 1.057573e-01 | 0.976 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 1.057573e-01 | 0.976 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 1.064072e-01 | 0.973 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 1.074158e-01 | 0.969 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 1.122331e-01 | 0.950 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 1.122331e-01 | 0.950 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 1.122331e-01 | 0.950 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 1.122541e-01 | 0.950 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 1.127969e-01 | 0.948 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 1.130601e-01 | 0.947 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 1.148097e-01 | 0.940 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 1.148097e-01 | 0.940 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 1.148097e-01 | 0.940 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 1.149724e-01 | 0.939 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 1.155197e-01 | 0.937 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 1.195407e-01 | 0.922 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 1.210379e-01 | 0.917 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 1.222685e-01 | 0.913 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 1.222685e-01 | 0.913 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 1.222685e-01 | 0.913 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 1.236172e-01 | 0.908 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.236172e-01 | 0.908 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 1.236172e-01 | 0.908 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 1.236172e-01 | 0.908 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 1.240509e-01 | 0.906 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 1.258546e-01 | 0.900 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 1.260098e-01 | 0.900 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 1.260098e-01 | 0.900 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 1.260098e-01 | 0.900 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 1.266375e-01 | 0.897 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 2.295936e-01 | 0.639 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 2.295936e-01 | 0.639 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 2.295936e-01 | 0.639 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 2.295936e-01 | 0.639 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 2.295936e-01 | 0.639 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 2.295936e-01 | 0.639 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 2.295936e-01 | 0.639 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 2.295936e-01 | 0.639 | 0 | 0 |
| RPIA deficiency: failed conversion of R5P to RU5P | R-HSA-5659996 | 2.295936e-01 | 0.639 | 0 | 0 |
| SARS-CoV-1 targets PDZ proteins in cell-cell junction | R-HSA-9692912 | 2.295936e-01 | 0.639 | 0 | 0 |
| Hereditary fructose intolerance | R-HSA-5657560 | 2.295936e-01 | 0.639 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function | R-HSA-9645722 | 2.295936e-01 | 0.639 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 2.295936e-01 | 0.639 | 0 | 0 |
| TGFBR2 MSI Frameshift Mutants in Cancer | R-HSA-3642279 | 2.295936e-01 | 0.639 | 0 | 0 |
| RPIA deficiency: failed conversion of RU5P to R5P | R-HSA-6791461 | 2.295936e-01 | 0.639 | 0 | 0 |
| Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1) | R-HSA-5619043 | 2.295936e-01 | 0.639 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 1.393029e-01 | 0.856 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 1.393029e-01 | 0.856 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 1.393029e-01 | 0.856 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 1.393029e-01 | 0.856 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 1.393029e-01 | 0.856 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 1.849037e-01 | 0.733 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 1.849037e-01 | 0.733 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 1.849037e-01 | 0.733 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 1.849037e-01 | 0.733 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 1.849037e-01 | 0.733 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 1.437839e-01 | 0.842 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 1.437839e-01 | 0.842 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 1.437839e-01 | 0.842 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 2.322244e-01 | 0.634 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 2.322244e-01 | 0.634 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 2.322244e-01 | 0.634 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 2.322244e-01 | 0.634 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.748563e-01 | 0.757 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 1.349674e-01 | 0.870 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 1.349674e-01 | 0.870 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 2.075769e-01 | 0.683 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 1.427676e-01 | 0.845 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 1.427676e-01 | 0.845 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 1.839145e-01 | 0.735 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 1.839145e-01 | 0.735 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 1.839145e-01 | 0.735 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 1.631070e-01 | 0.788 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 1.292771e-01 | 0.888 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 1.845226e-01 | 0.734 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 1.628765e-01 | 0.788 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 1.628765e-01 | 0.788 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 1.444250e-01 | 0.840 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 2.376232e-01 | 0.624 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 2.068939e-01 | 0.684 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 1.770791e-01 | 0.752 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 1.770791e-01 | 0.752 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 1.523515e-01 | 0.817 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 2.214366e-01 | 0.655 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 2.214366e-01 | 0.655 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 2.214366e-01 | 0.655 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 2.539951e-01 | 0.595 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 1.661020e-01 | 0.780 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 1.661020e-01 | 0.780 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 1.661020e-01 | 0.780 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 1.601830e-01 | 0.795 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 2.057374e-01 | 0.687 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 1.877485e-01 | 0.726 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 2.264002e-01 | 0.645 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 2.157079e-01 | 0.666 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 2.068939e-01 | 0.684 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 2.503332e-01 | 0.601 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 1.804134e-01 | 0.744 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 1.349674e-01 | 0.870 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 1.422573e-01 | 0.847 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 1.523515e-01 | 0.817 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 2.539951e-01 | 0.595 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 2.285106e-01 | 0.641 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 1.849037e-01 | 0.733 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 2.415137e-01 | 0.617 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 2.415137e-01 | 0.617 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 2.376232e-01 | 0.624 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 1.718612e-01 | 0.765 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 1.770791e-01 | 0.752 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 1.478715e-01 | 0.830 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 1.587403e-01 | 0.799 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 1.944855e-01 | 0.711 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 1.477007e-01 | 0.831 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 2.539951e-01 | 0.595 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 2.125374e-01 | 0.673 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 2.285106e-01 | 0.641 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 2.423473e-01 | 0.616 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 1.748563e-01 | 0.757 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 1.587403e-01 | 0.799 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 1.587403e-01 | 0.799 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 1.845226e-01 | 0.734 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 1.794440e-01 | 0.746 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 1.816171e-01 | 0.741 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 1.523515e-01 | 0.817 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 2.092500e-01 | 0.679 | 0 | 0 |
| Activation and oligomerization of BAK protein | R-HSA-111452 | 2.295936e-01 | 0.639 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 1.849037e-01 | 0.733 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 1.281180e-01 | 0.892 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 1.631070e-01 | 0.788 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 1.478715e-01 | 0.830 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 2.369830e-01 | 0.625 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 1.944855e-01 | 0.711 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 1.877485e-01 | 0.726 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 1.877485e-01 | 0.726 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 1.877485e-01 | 0.726 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 1.661020e-01 | 0.780 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 2.195518e-01 | 0.658 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 1.839145e-01 | 0.735 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 2.068939e-01 | 0.684 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 2.389456e-01 | 0.622 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 1.396774e-01 | 0.855 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 1.952558e-01 | 0.709 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 2.105964e-01 | 0.677 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 1.876657e-01 | 0.727 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 1.667112e-01 | 0.778 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 2.322244e-01 | 0.634 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 1.748563e-01 | 0.757 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 2.075769e-01 | 0.683 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 2.384131e-01 | 0.623 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 1.603293e-01 | 0.795 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 2.503332e-01 | 0.601 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 2.180098e-01 | 0.662 | 0 | 0 |
| Activation, translocation and oligomerization of BAX | R-HSA-114294 | 2.295936e-01 | 0.639 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 2.295936e-01 | 0.639 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 1.393029e-01 | 0.856 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 1.849037e-01 | 0.733 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 1.437839e-01 | 0.842 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 1.839145e-01 | 0.735 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 2.376232e-01 | 0.624 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 1.603748e-01 | 0.795 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 2.180098e-01 | 0.662 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 1.996419e-01 | 0.700 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 1.477007e-01 | 0.831 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 1.450199e-01 | 0.839 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 2.423473e-01 | 0.616 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 2.391939e-01 | 0.621 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 2.260883e-01 | 0.646 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 1.437839e-01 | 0.842 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 1.631070e-01 | 0.788 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 2.376232e-01 | 0.624 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 2.423473e-01 | 0.616 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 1.580433e-01 | 0.801 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 2.375197e-01 | 0.624 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 1.849037e-01 | 0.733 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 1.587403e-01 | 0.799 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 1.587403e-01 | 0.799 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 1.450199e-01 | 0.839 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 1.566801e-01 | 0.805 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 2.539951e-01 | 0.595 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 2.264002e-01 | 0.645 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 2.539951e-01 | 0.595 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 2.415137e-01 | 0.617 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 2.503332e-01 | 0.601 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 1.427676e-01 | 0.845 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 2.539951e-01 | 0.595 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 1.270860e-01 | 0.896 | 1 | 0 |
| Syndecan interactions | R-HSA-3000170 | 1.816171e-01 | 0.741 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 1.545775e-01 | 0.811 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 1.587403e-01 | 0.799 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 1.587403e-01 | 0.799 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 2.075769e-01 | 0.683 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 1.279168e-01 | 0.893 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 1.328979e-01 | 0.876 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 1.716988e-01 | 0.765 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 1.281180e-01 | 0.892 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 1.603293e-01 | 0.795 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 1.620483e-01 | 0.790 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 2.512353e-01 | 0.600 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 2.195518e-01 | 0.658 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 2.556690e-01 | 0.592 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 2.556690e-01 | 0.592 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 2.592472e-01 | 0.586 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 2.592472e-01 | 0.586 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 2.616025e-01 | 0.582 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 2.637947e-01 | 0.579 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 2.641560e-01 | 0.578 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 2.657326e-01 | 0.576 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 2.657326e-01 | 0.576 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 2.657326e-01 | 0.576 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 2.657326e-01 | 0.576 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 2.657326e-01 | 0.576 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 2.673283e-01 | 0.573 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 2.698830e-01 | 0.569 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 2.699488e-01 | 0.569 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 2.741428e-01 | 0.562 | 0 | 0 |
| Immune System | R-HSA-168256 | 2.757272e-01 | 0.560 | 1 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 2.762625e-01 | 0.559 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 2.762625e-01 | 0.559 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 2.764432e-01 | 0.558 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 2.784655e-01 | 0.555 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 2.784655e-01 | 0.555 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 2.784655e-01 | 0.555 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 2.784655e-01 | 0.555 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 2.785683e-01 | 0.555 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 2.801634e-01 | 0.553 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 2.801634e-01 | 0.553 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 2.801634e-01 | 0.553 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 2.801634e-01 | 0.553 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 2.801634e-01 | 0.553 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 2.801634e-01 | 0.553 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 2.825410e-01 | 0.549 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 2.857294e-01 | 0.544 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 2.857294e-01 | 0.544 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 2.857294e-01 | 0.544 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 2.899550e-01 | 0.538 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 2.899550e-01 | 0.538 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 2.899550e-01 | 0.538 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 2.899550e-01 | 0.538 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 2.899550e-01 | 0.538 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 2.916735e-01 | 0.535 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 2.916735e-01 | 0.535 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 2.916735e-01 | 0.535 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 2.923235e-01 | 0.534 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 2.928791e-01 | 0.533 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 2.934811e-01 | 0.532 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 2.935574e-01 | 0.532 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 2.935574e-01 | 0.532 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 2.944019e-01 | 0.531 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 2.944019e-01 | 0.531 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 2.944019e-01 | 0.531 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 2.944019e-01 | 0.531 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 2.944019e-01 | 0.531 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 2.944019e-01 | 0.531 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 2.997253e-01 | 0.523 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 3.033768e-01 | 0.518 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 3.033768e-01 | 0.518 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 3.033768e-01 | 0.518 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 3.033768e-01 | 0.518 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 3.080211e-01 | 0.511 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 3.080211e-01 | 0.511 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 3.080211e-01 | 0.511 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 3.102846e-01 | 0.508 | 1 | 1 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 3.102846e-01 | 0.508 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 3.110148e-01 | 0.507 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 3.110148e-01 | 0.507 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 3.111113e-01 | 0.507 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 3.114530e-01 | 0.507 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 3.114530e-01 | 0.507 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 3.114530e-01 | 0.507 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 3.154367e-01 | 0.501 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 3.202062e-01 | 0.495 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 3.234340e-01 | 0.490 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 3.234340e-01 | 0.490 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 3.234340e-01 | 0.490 | 0 | 0 |
| Abasic sugar-phosphate removal via the single-nucleotide replacement pathway | R-HSA-73930 | 3.238010e-01 | 0.490 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 3.238010e-01 | 0.490 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5660724 | 3.238010e-01 | 0.490 | 0 | 0 |
| Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) | R-HSA-5660686 | 3.238010e-01 | 0.490 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 3.238010e-01 | 0.490 | 0 | 0 |
| Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) | R-HSA-5619101 | 3.238010e-01 | 0.490 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 3.238010e-01 | 0.490 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5619081 | 3.238010e-01 | 0.490 | 0 | 0 |
| Defective TPMT causes TPMT deficiency | R-HSA-5578995 | 3.238010e-01 | 0.490 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 3.238010e-01 | 0.490 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 3.238010e-01 | 0.490 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 3.238010e-01 | 0.490 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 3.238010e-01 | 0.490 | 0 | 0 |
| ARL13B-mediated ciliary trafficking of INPP5E | R-HSA-5624958 | 3.238010e-01 | 0.490 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 3.238010e-01 | 0.490 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 3.238010e-01 | 0.490 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 3.253772e-01 | 0.488 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 3.253772e-01 | 0.488 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 3.278625e-01 | 0.484 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 3.278625e-01 | 0.484 | 0 | 0 |
| Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT) | R-HSA-5619070 | 3.278625e-01 | 0.484 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 3.278625e-01 | 0.484 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 3.278625e-01 | 0.484 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 3.278625e-01 | 0.484 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 3.278625e-01 | 0.484 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 3.286028e-01 | 0.483 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 3.301365e-01 | 0.481 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 3.305944e-01 | 0.481 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 3.305944e-01 | 0.481 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 3.308711e-01 | 0.480 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 3.308711e-01 | 0.480 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 3.337532e-01 | 0.477 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 3.467522e-01 | 0.460 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 3.467522e-01 | 0.460 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 3.467522e-01 | 0.460 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 3.467522e-01 | 0.460 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 3.493469e-01 | 0.457 | 0 | 0 |
| PKA activation | R-HSA-163615 | 3.526428e-01 | 0.453 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 3.526428e-01 | 0.453 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 3.526428e-01 | 0.453 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 3.540217e-01 | 0.451 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 3.725513e-01 | 0.429 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 3.725513e-01 | 0.429 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 3.725513e-01 | 0.429 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 3.746639e-01 | 0.426 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 3.746639e-01 | 0.426 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 3.746639e-01 | 0.426 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 3.746639e-01 | 0.426 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 3.746639e-01 | 0.426 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 3.746639e-01 | 0.426 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 3.762395e-01 | 0.425 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 3.762395e-01 | 0.425 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 3.762395e-01 | 0.425 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 3.781712e-01 | 0.422 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 3.795175e-01 | 0.421 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 3.795175e-01 | 0.421 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 3.818552e-01 | 0.418 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 3.818552e-01 | 0.418 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 3.818552e-01 | 0.418 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 3.818659e-01 | 0.418 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 3.818659e-01 | 0.418 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 3.818659e-01 | 0.418 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 3.831704e-01 | 0.417 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 3.881181e-01 | 0.411 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 3.937304e-01 | 0.405 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 3.991456e-01 | 0.399 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 3.991456e-01 | 0.399 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 3.991456e-01 | 0.399 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 3.996865e-01 | 0.398 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 4.049801e-01 | 0.393 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 4.059553e-01 | 0.392 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 4.062827e-01 | 0.391 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 4.064933e-01 | 0.391 | 0 | 0 |
| Signalling to ERK5 | R-HSA-198765 | 4.064933e-01 | 0.391 | 0 | 0 |
| Defective ALG9 causes CDG-1l | R-HSA-4720454 | 4.064933e-01 | 0.391 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 4.064933e-01 | 0.391 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 4.064933e-01 | 0.391 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 4.064933e-01 | 0.391 | 0 | 0 |
| ATF6B (ATF6-beta) activates chaperones | R-HSA-8874177 | 4.064933e-01 | 0.391 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 4.072727e-01 | 0.390 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 4.075792e-01 | 0.390 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 4.075792e-01 | 0.390 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 4.109128e-01 | 0.386 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 4.123702e-01 | 0.385 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 4.123702e-01 | 0.385 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 4.136835e-01 | 0.383 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 4.165386e-01 | 0.380 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 4.165386e-01 | 0.380 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 4.165386e-01 | 0.380 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 4.200742e-01 | 0.377 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 4.200742e-01 | 0.377 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 4.200742e-01 | 0.377 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 4.200742e-01 | 0.377 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 4.200742e-01 | 0.377 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 4.200742e-01 | 0.377 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 4.220029e-01 | 0.375 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 4.246629e-01 | 0.372 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 4.295847e-01 | 0.367 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 4.303073e-01 | 0.366 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 4.303073e-01 | 0.366 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 4.303073e-01 | 0.366 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 4.303073e-01 | 0.366 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 4.358699e-01 | 0.361 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 4.396718e-01 | 0.357 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 4.443141e-01 | 0.352 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 4.447382e-01 | 0.352 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 4.464861e-01 | 0.350 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 4.483343e-01 | 0.348 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 4.505522e-01 | 0.346 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 4.505522e-01 | 0.346 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 4.505522e-01 | 0.346 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 4.505522e-01 | 0.346 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 4.510538e-01 | 0.346 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 4.536676e-01 | 0.343 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 4.554042e-01 | 0.342 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 4.554042e-01 | 0.342 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 4.557649e-01 | 0.341 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 4.561971e-01 | 0.341 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 4.583012e-01 | 0.339 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 4.637339e-01 | 0.334 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 4.637339e-01 | 0.334 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 4.637339e-01 | 0.334 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 4.637339e-01 | 0.334 | 0 | 0 |
| Hypusine synthesis from eIF5A-lysine | R-HSA-204626 | 4.637339e-01 | 0.334 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 4.637339e-01 | 0.334 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 4.637339e-01 | 0.334 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 4.637339e-01 | 0.334 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 4.637339e-01 | 0.334 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 4.637339e-01 | 0.334 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 4.637339e-01 | 0.334 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 4.637339e-01 | 0.334 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 4.672833e-01 | 0.330 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 4.790773e-01 | 0.320 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 4.790773e-01 | 0.320 | 0 | 0 |
| Defective ABCC2 causes DJS | R-HSA-5679001 | 4.790773e-01 | 0.320 | 0 | 0 |
| Inhibition of nitric oxide production | R-HSA-9636249 | 4.790773e-01 | 0.320 | 0 | 0 |
| Intracellular oxygen transport | R-HSA-8981607 | 4.790773e-01 | 0.320 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 4.790773e-01 | 0.320 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 4.790773e-01 | 0.320 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 4.790773e-01 | 0.320 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 4.801842e-01 | 0.319 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 4.801842e-01 | 0.319 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 4.801842e-01 | 0.319 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 4.801842e-01 | 0.319 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 4.837242e-01 | 0.315 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 4.837242e-01 | 0.315 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 4.837242e-01 | 0.315 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 4.895747e-01 | 0.310 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 4.957961e-01 | 0.305 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 4.972564e-01 | 0.303 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 5.045689e-01 | 0.297 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 5.053921e-01 | 0.296 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 5.053921e-01 | 0.296 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 5.053921e-01 | 0.296 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 5.053921e-01 | 0.296 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 5.053921e-01 | 0.296 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 5.053921e-01 | 0.296 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 5.053921e-01 | 0.296 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 5.053921e-01 | 0.296 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 5.095011e-01 | 0.293 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 5.159051e-01 | 0.287 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 5.159051e-01 | 0.287 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 5.226286e-01 | 0.282 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 5.229506e-01 | 0.282 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 5.229506e-01 | 0.282 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 5.284885e-01 | 0.277 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 5.284885e-01 | 0.277 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 5.357283e-01 | 0.271 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 5.372859e-01 | 0.270 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 5.405679e-01 | 0.267 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 5.407317e-01 | 0.267 | 0 | 0 |
| Alternative complement activation | R-HSA-173736 | 5.427883e-01 | 0.265 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 5.427883e-01 | 0.265 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 5.427883e-01 | 0.265 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 5.427883e-01 | 0.265 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 5.427883e-01 | 0.265 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 5.427883e-01 | 0.265 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 5.427883e-01 | 0.265 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 5.448855e-01 | 0.264 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 5.448855e-01 | 0.264 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 5.448855e-01 | 0.264 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 5.448855e-01 | 0.264 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 5.469758e-01 | 0.262 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 5.469758e-01 | 0.262 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 5.469758e-01 | 0.262 | 1 | 1 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 5.469758e-01 | 0.262 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 5.493839e-01 | 0.260 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 5.556064e-01 | 0.255 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 5.568120e-01 | 0.254 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 5.568120e-01 | 0.254 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 5.585580e-01 | 0.253 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 5.615027e-01 | 0.251 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 5.615027e-01 | 0.251 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 5.746935e-01 | 0.241 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 5.746935e-01 | 0.241 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 5.750262e-01 | 0.240 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 5.750262e-01 | 0.240 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 5.750262e-01 | 0.240 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 5.750262e-01 | 0.240 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 5.751170e-01 | 0.240 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 5.759649e-01 | 0.240 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 5.768448e-01 | 0.239 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 5.768448e-01 | 0.239 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 5.768448e-01 | 0.239 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 5.768448e-01 | 0.239 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 5.821204e-01 | 0.235 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 5.821204e-01 | 0.235 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 5.821204e-01 | 0.235 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 5.821204e-01 | 0.235 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 5.821204e-01 | 0.235 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 5.821204e-01 | 0.235 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 5.821204e-01 | 0.235 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 5.825485e-01 | 0.235 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 5.947139e-01 | 0.226 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 5.948474e-01 | 0.226 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 5.953478e-01 | 0.225 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 5.987104e-01 | 0.223 | 0 | 0 |
| IRS activation | R-HSA-74713 | 5.987104e-01 | 0.223 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 5.987104e-01 | 0.223 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 5.987104e-01 | 0.223 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 5.987104e-01 | 0.223 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 5.987104e-01 | 0.223 | 0 | 0 |
| Activation of C3 and C5 | R-HSA-174577 | 5.987104e-01 | 0.223 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 5.987104e-01 | 0.223 | 0 | 0 |
| Toxicity of botulinum toxin type G (botG) | R-HSA-5250989 | 5.987104e-01 | 0.223 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 5.987104e-01 | 0.223 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 5.987104e-01 | 0.223 | 0 | 0 |
| Suppression of autophagy | R-HSA-9636569 | 5.987104e-01 | 0.223 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 5.987104e-01 | 0.223 | 0 | 0 |
| Inositol transporters | R-HSA-429593 | 5.987104e-01 | 0.223 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 5.987104e-01 | 0.223 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 5.987104e-01 | 0.223 | 0 | 0 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 5.987104e-01 | 0.223 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 5.987104e-01 | 0.223 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 5.987104e-01 | 0.223 | 0 | 0 |
| Assembly of Viral Components at the Budding Site | R-HSA-168316 | 5.987104e-01 | 0.223 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 5.998209e-01 | 0.222 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 5.998209e-01 | 0.222 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 6.053545e-01 | 0.218 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 6.054447e-01 | 0.218 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 6.054447e-01 | 0.218 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 6.054447e-01 | 0.218 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 6.054447e-01 | 0.218 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 6.054447e-01 | 0.218 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 6.065656e-01 | 0.217 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 6.130315e-01 | 0.213 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 6.137544e-01 | 0.212 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 6.151006e-01 | 0.211 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 6.151006e-01 | 0.211 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 6.170586e-01 | 0.210 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 6.170586e-01 | 0.210 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 6.170586e-01 | 0.210 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 6.170586e-01 | 0.210 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 6.170586e-01 | 0.210 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 6.170586e-01 | 0.210 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 6.170586e-01 | 0.210 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 6.170586e-01 | 0.210 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 6.170586e-01 | 0.210 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 6.170586e-01 | 0.210 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 6.184011e-01 | 0.209 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 6.184011e-01 | 0.209 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 6.184011e-01 | 0.209 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 6.237234e-01 | 0.205 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 6.237234e-01 | 0.205 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 6.237234e-01 | 0.205 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 6.237234e-01 | 0.205 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 6.327303e-01 | 0.199 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 6.327303e-01 | 0.199 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 6.327303e-01 | 0.199 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 6.327303e-01 | 0.199 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 6.342779e-01 | 0.198 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 6.342779e-01 | 0.198 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 6.370537e-01 | 0.196 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 6.392794e-01 | 0.194 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 6.467003e-01 | 0.189 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 6.467003e-01 | 0.189 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 6.467003e-01 | 0.189 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 6.477954e-01 | 0.189 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 6.477954e-01 | 0.189 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 6.477954e-01 | 0.189 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 6.477954e-01 | 0.189 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 6.477954e-01 | 0.189 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 6.477954e-01 | 0.189 | 0 | 0 |
| Cam-PDE 1 activation | R-HSA-111957 | 6.477954e-01 | 0.189 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 6.477954e-01 | 0.189 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 6.477954e-01 | 0.189 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 6.477954e-01 | 0.189 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 6.477954e-01 | 0.189 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 6.477954e-01 | 0.189 | 0 | 0 |
| Orexin and neuropeptides FF and QRFP bind to their respective receptors | R-HSA-389397 | 6.477954e-01 | 0.189 | 0 | 0 |
| Relaxin receptors | R-HSA-444821 | 6.477954e-01 | 0.189 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 6.477954e-01 | 0.189 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 6.477954e-01 | 0.189 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 6.497047e-01 | 0.187 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 6.497047e-01 | 0.187 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 6.497047e-01 | 0.187 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 6.497047e-01 | 0.187 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 6.497047e-01 | 0.187 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 6.586750e-01 | 0.181 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 6.586750e-01 | 0.181 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 6.586750e-01 | 0.181 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 6.586750e-01 | 0.181 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 6.586750e-01 | 0.181 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 6.593330e-01 | 0.181 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 6.608847e-01 | 0.180 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 6.651711e-01 | 0.177 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 6.678586e-01 | 0.175 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 6.687281e-01 | 0.175 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 6.692203e-01 | 0.174 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 6.712691e-01 | 0.173 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 6.723922e-01 | 0.172 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 6.774471e-01 | 0.169 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 6.774471e-01 | 0.169 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 6.800967e-01 | 0.167 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 6.800967e-01 | 0.167 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 6.800967e-01 | 0.167 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 6.800967e-01 | 0.167 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 6.800967e-01 | 0.167 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 6.800967e-01 | 0.167 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 6.830089e-01 | 0.166 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 6.832686e-01 | 0.165 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 6.832686e-01 | 0.165 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 6.832686e-01 | 0.165 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 6.832686e-01 | 0.165 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 6.832686e-01 | 0.165 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 6.876148e-01 | 0.163 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 6.897927e-01 | 0.161 | 0 | 0 |
| Chylomicron clearance | R-HSA-8964026 | 6.908790e-01 | 0.161 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 6.908790e-01 | 0.161 | 0 | 0 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | R-HSA-9912529 | 6.908790e-01 | 0.161 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 6.908790e-01 | 0.161 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 6.908790e-01 | 0.161 | 0 | 0 |
| Lactose synthesis | R-HSA-5653890 | 6.908790e-01 | 0.161 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 6.908790e-01 | 0.161 | 0 | 0 |
| CREB3 factors activate genes | R-HSA-8874211 | 6.908790e-01 | 0.161 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 6.973176e-01 | 0.157 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 7.050774e-01 | 0.152 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 7.050774e-01 | 0.152 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 7.065150e-01 | 0.151 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 7.065150e-01 | 0.151 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 7.065150e-01 | 0.151 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 7.082976e-01 | 0.150 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 7.082976e-01 | 0.150 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 7.082976e-01 | 0.150 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 7.082976e-01 | 0.150 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 7.082976e-01 | 0.150 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 7.082976e-01 | 0.150 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 7.082976e-01 | 0.150 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 7.095244e-01 | 0.149 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 7.098882e-01 | 0.149 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 7.143773e-01 | 0.146 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 7.151767e-01 | 0.146 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 7.151767e-01 | 0.146 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 7.212386e-01 | 0.142 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 7.275876e-01 | 0.138 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 7.275876e-01 | 0.138 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 7.284296e-01 | 0.138 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 7.284296e-01 | 0.138 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 7.286945e-01 | 0.137 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 7.286945e-01 | 0.137 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 7.286945e-01 | 0.137 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 7.286945e-01 | 0.137 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 7.286945e-01 | 0.137 | 0 | 0 |
| Synthesis of PIPs in the nucleus | R-HSA-8847453 | 7.286945e-01 | 0.137 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 7.286945e-01 | 0.137 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 7.286945e-01 | 0.137 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 7.286945e-01 | 0.137 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 7.286945e-01 | 0.137 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 7.286945e-01 | 0.137 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 7.322755e-01 | 0.135 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 7.322755e-01 | 0.135 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 7.322755e-01 | 0.135 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 7.322755e-01 | 0.135 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 7.343885e-01 | 0.134 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 7.343885e-01 | 0.134 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 7.343885e-01 | 0.134 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 7.343885e-01 | 0.134 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 7.343885e-01 | 0.134 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 7.343885e-01 | 0.134 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 7.367729e-01 | 0.133 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 7.465606e-01 | 0.127 | 0 | 0 |
| Disease | R-HSA-1643685 | 7.468770e-01 | 0.127 | 1 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 7.480051e-01 | 0.126 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 7.490377e-01 | 0.125 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 7.490377e-01 | 0.125 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 7.490377e-01 | 0.125 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 7.490377e-01 | 0.125 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 7.490377e-01 | 0.125 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 7.584635e-01 | 0.120 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 7.584635e-01 | 0.120 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 7.584635e-01 | 0.120 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 7.584635e-01 | 0.120 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 7.584635e-01 | 0.120 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 7.618859e-01 | 0.118 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 7.618859e-01 | 0.118 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 7.618859e-01 | 0.118 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 7.618859e-01 | 0.118 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 7.618859e-01 | 0.118 | 0 | 0 |
| Toxicity of botulinum toxin type B (botB) | R-HSA-5250958 | 7.618859e-01 | 0.118 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 7.618859e-01 | 0.118 | 0 | 0 |
| Fructose biosynthesis | R-HSA-5652227 | 7.618859e-01 | 0.118 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 7.618859e-01 | 0.118 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 7.618859e-01 | 0.118 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 7.618859e-01 | 0.118 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 7.618859e-01 | 0.118 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 7.618859e-01 | 0.118 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 7.642041e-01 | 0.117 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 7.644036e-01 | 0.117 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 7.660038e-01 | 0.116 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 7.683726e-01 | 0.114 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 7.683726e-01 | 0.114 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 7.688187e-01 | 0.114 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 7.749895e-01 | 0.111 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 7.749895e-01 | 0.111 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 7.796279e-01 | 0.108 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 7.806254e-01 | 0.108 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 7.806254e-01 | 0.108 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 7.806254e-01 | 0.108 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 7.806254e-01 | 0.108 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 7.806947e-01 | 0.108 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 7.806947e-01 | 0.108 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 7.864737e-01 | 0.104 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 7.864737e-01 | 0.104 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 7.864737e-01 | 0.104 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 7.910184e-01 | 0.102 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 7.910184e-01 | 0.102 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 7.910184e-01 | 0.102 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 7.910184e-01 | 0.102 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 7.910184e-01 | 0.102 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 7.910184e-01 | 0.102 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 7.910184e-01 | 0.102 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 7.910184e-01 | 0.102 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 7.910184e-01 | 0.102 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 7.980892e-01 | 0.098 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 8.008502e-01 | 0.096 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 8.009817e-01 | 0.096 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 8.009817e-01 | 0.096 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 8.009817e-01 | 0.096 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 8.009817e-01 | 0.096 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 8.033854e-01 | 0.095 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 8.039476e-01 | 0.095 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 8.065606e-01 | 0.093 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 8.105801e-01 | 0.091 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 8.105801e-01 | 0.091 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 8.106405e-01 | 0.091 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 8.165881e-01 | 0.088 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 8.165881e-01 | 0.088 | 0 | 0 |
| TET1,2,3 and TDG demethylate DNA | R-HSA-5221030 | 8.165881e-01 | 0.088 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 8.165881e-01 | 0.088 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 8.165881e-01 | 0.088 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 8.165881e-01 | 0.088 | 0 | 0 |
| CASP4 inflammasome assembly | R-HSA-9948001 | 8.165881e-01 | 0.088 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 8.165881e-01 | 0.088 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 8.165881e-01 | 0.088 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 8.165881e-01 | 0.088 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 8.165881e-01 | 0.088 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 8.165881e-01 | 0.088 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 8.191560e-01 | 0.087 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 8.196425e-01 | 0.086 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 8.196425e-01 | 0.086 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 8.196425e-01 | 0.086 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 8.196425e-01 | 0.086 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 8.196425e-01 | 0.086 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 8.196425e-01 | 0.086 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 8.196425e-01 | 0.086 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 8.312779e-01 | 0.080 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 8.312779e-01 | 0.080 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 8.338360e-01 | 0.079 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 8.338946e-01 | 0.079 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 8.367178e-01 | 0.077 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 8.367178e-01 | 0.077 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 8.367178e-01 | 0.077 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 8.367178e-01 | 0.077 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 8.367178e-01 | 0.077 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 8.367178e-01 | 0.077 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 8.367178e-01 | 0.077 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 8.370497e-01 | 0.077 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 8.370497e-01 | 0.077 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 8.389999e-01 | 0.076 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 8.390306e-01 | 0.076 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 8.390306e-01 | 0.076 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 8.390306e-01 | 0.076 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 8.390306e-01 | 0.076 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 8.390306e-01 | 0.076 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 8.390306e-01 | 0.076 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 8.390306e-01 | 0.076 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 8.390306e-01 | 0.076 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 8.390306e-01 | 0.076 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 8.390306e-01 | 0.076 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 8.390306e-01 | 0.076 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 8.390306e-01 | 0.076 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 8.390306e-01 | 0.076 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 8.406393e-01 | 0.075 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 8.410251e-01 | 0.075 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 8.422691e-01 | 0.075 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 8.474779e-01 | 0.072 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 8.474779e-01 | 0.072 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 8.523163e-01 | 0.069 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 8.523163e-01 | 0.069 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 8.523163e-01 | 0.069 | 0 | 0 |
| Vitamin C (ascorbate) metabolism | R-HSA-196836 | 8.523163e-01 | 0.069 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 8.555980e-01 | 0.068 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 8.560251e-01 | 0.068 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 8.587281e-01 | 0.066 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 8.587281e-01 | 0.066 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 8.587281e-01 | 0.066 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 8.587281e-01 | 0.066 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 8.587281e-01 | 0.066 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 8.587281e-01 | 0.066 | 0 | 0 |
| Endosomal/Vacuolar pathway | R-HSA-1236977 | 8.587281e-01 | 0.066 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 8.587281e-01 | 0.066 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 8.588161e-01 | 0.066 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 8.588161e-01 | 0.066 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 8.599647e-01 | 0.066 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 8.603481e-01 | 0.065 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 8.603481e-01 | 0.065 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 8.665435e-01 | 0.062 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 8.677860e-01 | 0.062 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 8.677860e-01 | 0.062 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 8.677860e-01 | 0.062 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 8.679443e-01 | 0.062 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 8.679443e-01 | 0.062 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 8.690403e-01 | 0.061 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 8.729766e-01 | 0.059 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 8.750793e-01 | 0.058 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 8.760163e-01 | 0.057 | 0 | 0 |
| Acetylation | R-HSA-156582 | 8.760163e-01 | 0.057 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 8.760163e-01 | 0.057 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 8.760163e-01 | 0.057 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 8.760163e-01 | 0.057 | 0 | 0 |
| Maple Syrup Urine Disease | R-HSA-9865114 | 8.760163e-01 | 0.057 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 8.760163e-01 | 0.057 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 8.760163e-01 | 0.057 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 8.760163e-01 | 0.057 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 8.760163e-01 | 0.057 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 8.765759e-01 | 0.057 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 8.765759e-01 | 0.057 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 8.782309e-01 | 0.056 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 8.795014e-01 | 0.056 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 8.795014e-01 | 0.056 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 8.795014e-01 | 0.056 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 8.795014e-01 | 0.056 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 8.807383e-01 | 0.055 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 8.807383e-01 | 0.055 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 8.807383e-01 | 0.055 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 8.807383e-01 | 0.055 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 8.809325e-01 | 0.055 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 8.818925e-01 | 0.055 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 8.827066e-01 | 0.054 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 8.827066e-01 | 0.054 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 8.884700e-01 | 0.051 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 8.891946e-01 | 0.051 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 8.891946e-01 | 0.051 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 8.899272e-01 | 0.051 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 8.899272e-01 | 0.051 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 8.903226e-01 | 0.050 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 8.911897e-01 | 0.050 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 8.911897e-01 | 0.050 | 0 | 0 |
| Microbial factors inhibit CASP4 activity | R-HSA-9956593 | 8.911897e-01 | 0.050 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 8.911897e-01 | 0.050 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 8.911897e-01 | 0.050 | 0 | 0 |
| rRNA modification in the mitochondrion | R-HSA-6793080 | 8.911897e-01 | 0.050 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 8.922051e-01 | 0.050 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 8.924213e-01 | 0.049 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 8.927269e-01 | 0.049 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 8.927269e-01 | 0.049 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 8.927269e-01 | 0.049 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 8.957658e-01 | 0.048 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 8.976354e-01 | 0.047 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 8.984900e-01 | 0.046 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 9.011582e-01 | 0.045 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.019718e-01 | 0.045 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.019718e-01 | 0.045 | 0 | 0 |
| Assembly of active LPL and LIPC lipase complexes | R-HSA-8963889 | 9.019946e-01 | 0.045 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 9.019946e-01 | 0.045 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.021385e-01 | 0.045 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 9.045069e-01 | 0.044 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 9.045069e-01 | 0.044 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 9.045069e-01 | 0.044 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 9.045069e-01 | 0.044 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 9.045069e-01 | 0.044 | 0 | 0 |
| Glycerophospholipid catabolism | R-HSA-6814848 | 9.045069e-01 | 0.044 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 9.045069e-01 | 0.044 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 9.045069e-01 | 0.044 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 9.045069e-01 | 0.044 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 9.084527e-01 | 0.042 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 9.117101e-01 | 0.040 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 9.117101e-01 | 0.040 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 9.138699e-01 | 0.039 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 9.161950e-01 | 0.038 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 9.161950e-01 | 0.038 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 9.161950e-01 | 0.038 | 0 | 0 |
| Protein repair | R-HSA-5676934 | 9.161950e-01 | 0.038 | 0 | 0 |
| Dopamine clearance from the synaptic cleft | R-HSA-379401 | 9.161950e-01 | 0.038 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 9.161950e-01 | 0.038 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 9.161950e-01 | 0.038 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 9.161950e-01 | 0.038 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 9.205163e-01 | 0.036 | 0 | 0 |
| Linoleic acid (LA) metabolism | R-HSA-2046105 | 9.205163e-01 | 0.036 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 9.205163e-01 | 0.036 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 9.205163e-01 | 0.036 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.234738e-01 | 0.035 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 9.255411e-01 | 0.034 | 0 | 0 |
| Entry of Influenza Virion into Host Cell via Endocytosis | R-HSA-168275 | 9.264530e-01 | 0.033 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 9.264530e-01 | 0.033 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 9.264530e-01 | 0.033 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 9.264530e-01 | 0.033 | 0 | 0 |
| Activation of the phototransduction cascade | R-HSA-2485179 | 9.264530e-01 | 0.033 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 9.264530e-01 | 0.033 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 9.264530e-01 | 0.033 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 9.264530e-01 | 0.033 | 0 | 0 |
| Virus Assembly and Release | R-HSA-168268 | 9.264530e-01 | 0.033 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.267527e-01 | 0.033 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 9.284902e-01 | 0.032 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 9.284902e-01 | 0.032 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.297852e-01 | 0.032 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 9.350261e-01 | 0.029 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 9.354560e-01 | 0.029 | 0 | 0 |
| Heme assimilation | R-HSA-9927020 | 9.354560e-01 | 0.029 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 9.354560e-01 | 0.029 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 9.354560e-01 | 0.029 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 9.354560e-01 | 0.029 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 9.354560e-01 | 0.029 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 9.354560e-01 | 0.029 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.382363e-01 | 0.028 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.382363e-01 | 0.028 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.407862e-01 | 0.027 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 9.422231e-01 | 0.026 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 9.422231e-01 | 0.026 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 9.433573e-01 | 0.025 | 0 | 0 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 9.433573e-01 | 0.025 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 9.433573e-01 | 0.025 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 9.435965e-01 | 0.025 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 9.453414e-01 | 0.024 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 9.459998e-01 | 0.024 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 9.481105e-01 | 0.023 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 9.502918e-01 | 0.022 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 9.502918e-01 | 0.022 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 9.502918e-01 | 0.022 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 9.502918e-01 | 0.022 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 9.534227e-01 | 0.021 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 9.535127e-01 | 0.021 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.535670e-01 | 0.021 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 9.563777e-01 | 0.019 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 9.563777e-01 | 0.019 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 9.563777e-01 | 0.019 | 0 | 0 |
| HDL remodeling | R-HSA-8964058 | 9.563777e-01 | 0.019 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 9.571664e-01 | 0.019 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.574589e-01 | 0.019 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 9.582124e-01 | 0.019 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 9.605556e-01 | 0.017 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 9.617188e-01 | 0.017 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.617188e-01 | 0.017 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 9.617188e-01 | 0.017 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.617188e-01 | 0.017 | 0 | 0 |
| Synthesis of very long-chain fatty acyl-CoAs | R-HSA-75876 | 9.617255e-01 | 0.017 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.636532e-01 | 0.016 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.646829e-01 | 0.016 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 9.664062e-01 | 0.015 | 0 | 0 |
| Abacavir metabolism | R-HSA-2161541 | 9.664062e-01 | 0.015 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 9.664062e-01 | 0.015 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.664062e-01 | 0.015 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.664134e-01 | 0.015 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 9.664134e-01 | 0.015 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.664134e-01 | 0.015 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 9.696351e-01 | 0.013 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 9.699095e-01 | 0.013 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.699095e-01 | 0.013 | 0 | 0 |
| Metabolism of Angiotensinogen to Angiotensins | R-HSA-2022377 | 9.705199e-01 | 0.013 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 9.730532e-01 | 0.012 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.730532e-01 | 0.012 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 9.730532e-01 | 0.012 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 9.730532e-01 | 0.012 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.730632e-01 | 0.012 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.741300e-01 | 0.011 | 0 | 0 |
| Cellular hexose transport | R-HSA-189200 | 9.741300e-01 | 0.011 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 9.741300e-01 | 0.011 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.746868e-01 | 0.011 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.766125e-01 | 0.010 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 9.769059e-01 | 0.010 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 9.772983e-01 | 0.010 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.772983e-01 | 0.010 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 9.772983e-01 | 0.010 | 0 | 0 |
| Mitochondrial mRNA modification | R-HSA-9937008 | 9.772983e-01 | 0.010 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 9.772983e-01 | 0.010 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 9.772983e-01 | 0.010 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 9.800787e-01 | 0.009 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.800787e-01 | 0.009 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 9.806943e-01 | 0.008 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.806943e-01 | 0.008 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 9.808615e-01 | 0.008 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.825187e-01 | 0.008 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 9.825187e-01 | 0.008 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 9.825187e-01 | 0.008 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 9.825187e-01 | 0.008 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 9.831989e-01 | 0.007 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 9.840778e-01 | 0.007 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 9.846599e-01 | 0.007 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.846599e-01 | 0.007 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.846599e-01 | 0.007 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 9.846599e-01 | 0.007 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 9.846599e-01 | 0.007 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.862145e-01 | 0.006 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.862145e-01 | 0.006 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 9.865390e-01 | 0.006 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.866277e-01 | 0.006 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.881378e-01 | 0.005 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 9.881881e-01 | 0.005 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.882079e-01 | 0.005 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.882079e-01 | 0.005 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.909050e-01 | 0.004 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.910062e-01 | 0.004 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 9.912418e-01 | 0.004 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.913160e-01 | 0.004 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.918346e-01 | 0.004 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.918346e-01 | 0.004 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.920194e-01 | 0.003 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.923984e-01 | 0.003 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.931076e-01 | 0.003 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.937867e-01 | 0.003 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.937867e-01 | 0.003 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.938554e-01 | 0.003 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.943568e-01 | 0.002 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.944615e-01 | 0.002 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.949679e-01 | 0.002 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.949732e-01 | 0.002 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.950643e-01 | 0.002 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 9.952691e-01 | 0.002 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.958490e-01 | 0.002 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.958915e-01 | 0.002 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.960830e-01 | 0.002 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.960898e-01 | 0.002 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.961065e-01 | 0.002 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 9.963577e-01 | 0.002 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.963577e-01 | 0.002 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.963678e-01 | 0.002 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 9.968042e-01 | 0.001 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.968042e-01 | 0.001 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.968042e-01 | 0.001 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.968944e-01 | 0.001 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.968944e-01 | 0.001 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 9.970562e-01 | 0.001 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.971483e-01 | 0.001 | 0 | 0 |
| Diseases associated with N-glycosylation of proteins | R-HSA-3781860 | 9.975397e-01 | 0.001 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.975677e-01 | 0.001 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.977441e-01 | 0.001 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.978413e-01 | 0.001 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 9.978413e-01 | 0.001 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 9.978413e-01 | 0.001 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.978413e-01 | 0.001 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.978921e-01 | 0.001 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.982899e-01 | 0.001 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.986243e-01 | 0.001 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.987025e-01 | 0.001 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.988776e-01 | 0.000 | 0 | 0 |
| Methylation | R-HSA-156581 | 9.988776e-01 | 0.000 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.988776e-01 | 0.000 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.989855e-01 | 0.000 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 9.990093e-01 | 0.000 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.990153e-01 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.990389e-01 | 0.000 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.992321e-01 | 0.000 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.994018e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.994018e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.994024e-01 | 0.000 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.994166e-01 | 0.000 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.994689e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.995221e-01 | 0.000 | 0 | 0 |
| Cytosolic sulfonation of small molecules | R-HSA-156584 | 9.995509e-01 | 0.000 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 9.995509e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.996286e-01 | 0.000 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.996614e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.996705e-01 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.997406e-01 | 0.000 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.997953e-01 | 0.000 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.997953e-01 | 0.000 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.998396e-01 | 0.000 | 0 | 0 |
| Sialic acid metabolism | R-HSA-4085001 | 9.998424e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.998513e-01 | 0.000 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.998618e-01 | 0.000 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.998618e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.998836e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.998984e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.999203e-01 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.999324e-01 | 0.000 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.999447e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.999506e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.999550e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999569e-01 | 0.000 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.999621e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 9.999627e-01 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.999673e-01 | 0.000 | 0 | 0 |
| Metal ion assimilation from the host | R-HSA-9638482 | 9.999673e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999827e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.999840e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.999847e-01 | 0.000 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.999885e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.999885e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999902e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.999912e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.999913e-01 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.999914e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999942e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999947e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.999960e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999973e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.999980e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999983e-01 | 0.000 | 0 | 0 |
| Scavenging of heme from plasma | R-HSA-2168880 | 9.999991e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.999992e-01 | 0.000 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.999992e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.999994e-01 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.999996e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999997e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.999998e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.999999e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999999e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999999e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.999999e-01 | 0.000 | 0 | 0 |
| Initial triggering of complement | R-HSA-166663 | 9.999999e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 1.000000e+00 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000e+00 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 1.000000e+00 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 1.000000e+00 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | -0.000 | 0 | 0 |